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Of the plethora of parasitic diseases that afflict mankind, malaria remains the most 
prevalent. The disease has caused severe global health problems, putting 3.2 billion 
people at risk of developing the Plasmodium infection. With current front-line 
treatments such as the artemisinins showing early warning signs of resistance, new 
novel drug leads are needed to ensure the safety of the populations at risk. With 
resistance growing, the development of new antimalarials is still slow as a result of 
tedious and prolonged discovery pipelines. Traditionally, antimalarial drug discoveries 
have derived from natural products (e.g. quinine and artemisinin derivatives). New 
natural product usage has diminished during the past few decades as a result of 
advances in molecular target detection and high-throughput screening technologies. 
Technical difficulties associated with the natural product extraction process, further 
compounded the issues. This study aims to investigate the potential antimalarial 
activity of Trametes versicolor and Acacia nilotica using solvent extracts in an in vitro 
study on Plasmodium falciparum (strain K1). Species validation from different 
collection sites was carried out using comparison of spectra generated with Fourier 
transform infra-red spectroscopy. To test drug efficiency, the parasites were exposed 
to the compounds for 48- and 72-hour incubations at trophozoite and ring stage. The 
specific doses for exposure were concentrations of 12.5 μg/ml, 25 μg/ml, 50 μg/ml, 
100 μg/ml and 200 μg/ml, for each extracted compound. MTT assays were performed 
alongside parasite IC50 studies in order to define the toxicity profiles.  
48 hours cycle IC50 values for T. versicolor and A. nilotica ethanol extractions were 
45.54 ± 1.12 μg/ml and 45.54 ± 1.12 μg/ml while the 72-hour cycle was 27.47 ± 1.09 
μg/ml and 37.3 ± 1.07 μg/ml on the multi-drug resistant strain K1 of Plasmodium 
falciparum. The methanol extraction on the other hand gave IC50 values of 20.2 ± 1.11 
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μg/ml after 48 hours cycle and 44.3 ± 1.06 μg/ml after 72 -hours for A. nilotica. The 
cytotoxicity assay carried out on HepG2 gave IC50 values of 51.6 ± 1.2 μg/ml for T. 
versicolor and 29.1 ± 1.07 μg/ml for A. nilotica ethanol extract. The cytotoxicity assay 
indicated a very narrow therapeutic index for both the T. versicolor (TI =1) and A. 
nilotica (TI = 0.6). However, given the previously published anti-cancer properties for 
both plant products, the use of the traditional HepG2 model for cytotoxicity is debated. 
This study confirmed these natural products as potential leads for new novel drug 
development. The evidence presented justifies further evaluation and validation of T. 



















CHAPTER ONE  
INTRODUCTION  
1.1 Malaria: a historical perspective  
Malaria is responsible for more deaths than any other cause in human history, 
including war, famine and disease. The disease, in fact, predates humanity. The oldest 
amber-preserved mosquito specimen containing a plasmodial infection dates back to 
30 million years.  Humans have been evolving alongside malaria for thousands of 
years, with resulting alterations to the genetic makeup of certain groups due to natural 
selection (Carter & Mendis, 2002). 
In written history, incidents of malaria have been recorded as far back as 4000 years. 
Its symptoms are documented in Chinese texts (2700 BC), Egyptian papyri (1570 BC) 
and Indian scripts dating back to the 6th century BC (Cox, 2010). The ancient texts 
give a detailed description of the hallmark symptoms of malaria, including tertian and 
quartan fevers and hepato-splenomegaly. In 4th century BC malaria plagued ancient 
Greece causing major declines in populations. In addition to historical symptomatic 
descriptions, Egyptian mummies have shown evidence of Plasmodium falciparum 
infection from 800 BC during the Fayum depression (Lalremuata et al., 2013). Through 
Darwinian descent, malaria significantly impacted colonisation, exploration and 
development of the world we know today (Harrison, 1978). Historical figures including 
Alexander the Great and Pope Gregory V are suspected to have fallen victim to the 
disease (Carter and Mendis 2002; Harrison, 1978). During the time of the world wars, 
malaria alongside other infectious diseases impacted the wars significantly. For every 
man lost as a direct impact from the war, another life was lost due to malaria. The war 
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time conditions also contributed to enhancing the spread of the disease (Cox, 2002; 
Harrison, 1978). 
The official name ‘malaria’ arose from the association of the disease with ‘bad air’ 
arising from marshy areas. This misguided belief associated the disease with miasmas 
(bad air) the Italian translation ‘mal’aria’, coming from the swamps. However, it would 
be many centuries and millions of deaths until the transmitter and transmission of the 
disease was fully understood (Stuart, 2004).  
Through the middle-ages, malaria continued to spread across Europe and even into 
England, where it was given the name Ague (swamp fever). The disease became so 
popular that many literary works including William Shakespeare referred to it.  Today, 
although malaria is a huge problem for people living in South America, the disease did 
not actually exist in that part of the world until after the Columbian exchange. European 
settlers who were already infected with the disease when they arrived, carried the 
disease with them, allowing native mosquitoes to become infected and thus furthering 
the spread of the disease.  
As medical studies advanced through history, the discovery of bacteria in 1676 by 
Antoni van Leeuwenhoek along with the theory that microorganisms are responsible 
as the lead cause of infectious diseases by Louis Pasteur and Robert Koch in 1878-
1879 (Cox, 2010), fuelled interest in discovering the causative agent of malaria. The 
discovery of the Protozoan parasite in 1880 by Charles Louis Alphonse Laveran (cox, 
2010) preceded the discovery that mosquitoes were the responsible vector firstly for 
avian malaria in 1897 and then human malaria between 1898 and 1900 by Italian 
scientist Giovanni Battista Grassi (Cox, 2010). The stages of the parasite’s life cycle 
were finally identified in 1948 (Stuart, 2004) 
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1.2 Malaria today  
The protozoan, parasitic disease malaria is spread through the bites of female 
Anopheles mosquitoes. The mosquito’s saliva infected with the sporozoites of the 
Plasmodium parasites is responsible for initiating the infection in humans. The disease 
is found in more than 90 countries world-wide, leaving 3 billion people at high risk of 
infection. The disease is currently more associated with tropical and sub-tropical 
regions including Africa, Asia and the South Americas.  
The who November (2017) report, estimates 219 million cases of malaria infections 
worldwide with 433000 deaths. For 1017 The highest concentration of reported 
malaria comes from Africa, with 200 million confirmed cases (92%) followed by south 
east Asia (5%).  Fifteen countries in sub-Saharan Arica and India made up 80% of the 
world’s malaria burden, with Nigeria carrying the highest burden at 19% (WHO, 2017).  
All WHO regions that are associated with malaria have shown signs of the reduction 
of mortality in 2017, compared to 2010, apart from the Americas. The most significant 
decline being in South-east Asia with a reduction of 54% closely followed by Africa at 





Figure 1.1 Malaria impacted areas Showing a world map of current countries that are being affected 
yet controlled shown in red. Countries that are on track to eliminate malaria are highlighted in blue, and 
the countries that are malaria free represented in green (source: Cotter et al., 2013). 
There are five plasmodial species that are known to transmit the disease to humans. 
P. falciparum, is the most common and virulent species out of all the five mentioned, 
with a wide geographical distribution in subtropical and tropical areas. It is the most 
common due to its rapid multiplication rates once inside the host. Plasmodium 
falciparum is the most prevalent malaria parasite in the WHO African Region, 
accounting for an estimated 99.7% malaria cases in 2017, as well as in the WHO 
regions of South-East Asia (62.8%), the Eastern Mediterranean (69%) and the 
Western Pacific (71.9%) (WHO, 2017). P. vivax a second species, is found throughout 
Asia, parts of Africa and Latin America. P. vivax is the predominant parasite in the 
Americas, representing 74.1% of malaria cases (WHO, 2017). P. ovale, is found in 
Africa and the western pacific and P. malariae is found in all malaria affected countries. 
Finally, P. knowlesi – this is a zoonotic monkey malaria that has recently been found 
to infect humans and is found throughout southeast Asia (Mita & Tanabe, 2012) 
infecting humans due to the increased contact with nature as a result of deforestation. 
Out of the five known species mentioned, the experiments presented in this thesis 
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focuses on a P. falciparum strain named K1 that has known multi-drug resistant 
properties and is a genetic clone derived from the natural parasite (Gifted by Prof John 
Hyde, University of Manchester). K1 when cultured in vitro is resistant to chloroquine, 
pyrimethamine and Sulfadoxine, making it an ideal test subject for anti-malarial 
research as is it can also be used as a control to determine the sensitivity of other 
antimalarials and antibiotics (Agarwal et al., 2017) 
 
 1.3 Anopheles mosquito  
 
Anopheles mosquitoes are found worldwide excluding Antarctica, with the capability 
to spread malaria via different species in several geographic locations. Within these 
regions, different environments support a specific species. There have been 
approximately 3,500 described species of mosquito that are divided into 41 genera 
groups. Malaria transmitted to humans can only be transmitted via the female 
mosquitos belonging to the genus Anopheles. There are over 400 known species of 
Anopheles, however, only 30-40 are known to be vectors of the malaria parasite. The 
remaining Anopheles mosquitoes are not able to sustain the development of the 
parasite (Kamareddine, 2012; Gomes et al., 2016). The most problematic Anopheles 
mosquito, Anopheles gambiae is found predominantly in sub-Saharan Africa. A 
gambiae, a known, highly efficient vector of P. falciparum, feeds primarily on human 
hosts (Mattah et al., 2017). 
All mosquito species including Anopheles, undergo four life stages in the completion 
of the life cycle (egg, larva, pupa, and adult). The first three stages are aquatic until 
the mosquito reaches adult stage dependent on surroundings and temperature (Beck-
Johnson et al., 2017). The male mosquitos do not bite and therefore do not transmit 
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the disease. The females have a short-lived life span resulting in a small proportion of 
the females living the required amount of time (usually 10 days) to pass on the malaria 
parasite (Crans, 2004).  
The adult female mosquito lays up to 200 eggs at a time. These eggs are laid one by 
one directly into the water supported by floats on each side of the egg (Crans, 2004). 
Dependant on the climate, eggs can hatch 2-3 days after being laid in more tropical 
regions, however in much cooler climates the eggs can take up to 2-3 weeks until they 
reach the larval stage.  
During the larval stage, they acquire a developed head contain mouth brushes that 
are used for feeing on algae, bacteria and other microorganisms. They have a thorax 
and a segmented abdomen however at this stage possess no legs. Unlike many other 
mosquito species, Anopheles do not have a siphon used for respiratory purposes and 
therefore lie parallel with the water surface in order to breath (Crans, 2004). The larvae 
develop in 4 stages and after each stage, shed their exoskeleton in order to grow 
before metamorphosing into pupae. 
During the pupae life stage, the mosquito does not feed for several days, instead the 
mosquito undergoes extreme metamorphosis. The head and thorax combine which 
then forms the cephalothorax resulting in the abdomen curving underneath (Crans, 
2004). The pupae then use a pair of breathing trumpets that are located on the 
cephalothorax to breath at the surface of the water. After a few days, dependant on 
temperature, the adult mosquito emerges from the dorsal surface on the surface of the 
water (Beck-Johnson et al., 2017). 
The head of the adult mosquito possess the proboscis, the part of the mosquito that 
is used for feeding along with two sensory palps. The head also contains the antennae 
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used to detect the mosquitoes host emissions. The abdomen of the mosquito 
specialises in the digestion of blood into proteins to sustain egg development.   
The Anopheles life cycle will then continue repeating until the female dies. As the 
female usually lives up to 2 weeks, her chances of survival mainly depend of 
temperature and obtaining a blood meal while avoiding many host defences (Beck-
Johnson et al., 2017). 
 
1.4 Plasmodium falciparum Life Cycle  
 
P. falciparum parasite requires two hosts in order to complete its life cycle, the 
mosquito vector along with the human host (Gomes et al., 2016). During the time spent 
within the human host, the parasite has two development stages, the asymptomatic 
pre-erythrocytic stage which is also known as the hepatic stage, along with 
symptomatic erythrocytic stage. The symptomatic erythrocytic stage is what causes 
pathologies linked with human infection (Garg et al., 2013; Fairhurst and Dondrop, 
2016). Once inside the mosquito is it known as the sporogonic cycle 
being in the vectors mid gut. Once the Anopheles mosquito ingests a blood meal from 
a human host the male gametocytes (microgametocytes) and female gametocytes 
(macrogametocytes) are also ingested. The reproduction cycle that takes place inside 
the mosquito is known as the sporogonic cycle. After injection, the parasites travel into 
the mosquito’s midgut where the macro/microgametocytes form together to produce 
a zygote. The zygote develops into an ookinete, where they then penetrate the midgut 
wall forming oocyst. The oocyst continues to grow, finally rupturing releasing the 
sporozoites that was growing inside it. The sporozoites then travel to the mosquito’s 
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salivary glands where it is then able to be injected into the human host (Garg et al., 
2013; Gomes et al., 2016). 
Once the female Anopheles mosquito take her blood meal, the sporozoites are 
injected into the host via the mosquito’s proboscis (Soulard et al., 2015) where they 
make their way into the hosts blood stream. The sporozoites that are injected into the 
blood travel to the liver and become the hepatic part of the life cycle, invading the 
hepatocytes. Once there, they differentiate and multiply into schizonts, which when 
fully grown contain several thousand hepatic merozoites. The merozoites then are 
released back into the blood stream where they become the erythrocytic part of the 
life cycle after invading the red blood cells (RBCs) (Soulard et al., 2015). The 
merozoites start off by invading the RBCs and then transform into what is called the 
ring stage due to appearance under the microscope resembling a signet ring. The 
rings then develop into early and late trophozoites, which then develop into schizonts. 
The schizonts burst open releasing 32 daughter clones into the hosts blood stream, 
further invading the remaining non-infected RBCs (Gomes et al., 2016). During this 
cycle some or the parasites differentiate into the gametocyte form (Soulard et al., 
2015) where they are then taken up by the mosquito during a blood meal and the full 





1.5 Symptoms and Diagnosis  
 
Clinical symptoms are the first signs patients will show when infected with malaria. P. 
falciparum being the most lethal is capable of causing severe disease characterised 
by the parasite’s ability to sequester in vital organs including the brain, resulting in 
cerebral malaria (coma). These symptoms include sickness, fever, headaches, 
tiredness which eventually progress to confusion, delirium and progressive loss of 
consciousness, coma and death if not treated effectively. Upon diagnosis, the patient’s 
travel history and geographical location should always be taken into consideration. In 
Figure 1.2 The complete life cycle of plasmodium showing both the human and mosquito cycle. 
Section A is showing the Exo-erythrocytic cycle, section B is showing the Erythrocytic cycle and 
Section C is showing the sporogonic cycle within the mosquito. Taken from (Centre for disease 
control (CDC), 2019) 
20 
 
severe malaria, clinical symptoms could also include renal failure, severe anaemia, 
jaundice and respiratory difficulties. These symptoms along with the flu like ones can 
be enough to determine if a person has malaria, but a laboratory test should always 
be carried out to determine the presence of malarial parasites in the blood.  
The most used method to detect malaria in the blood stream is microscopy. This 
procedure involves a drop of the patients’ blood thinly spread out over a glass slide 
and stained with Giemsa. This method of detection however can prove difficult at times 
and requires a degree of training.  Antigen detection kits are a new way of detection 
for the parasite. Rapid diagnostic tests (RDTs) aim to give results in a little as 2-12 
minutes, however these have shown to be not as effective when the parasite count is 
low (Cook et al., 2015). These tests do prove effective as an alternative to microscopy 
when available. Tests using polymerase chain reactions (PCR) are a lot more sensitive 
in detecting the presence of Plasmodium by amplifying the parasites DNA. Although 
more sensitive, this method takes time and has to be conducted in the laboratory with 
appropriate facilities, a condition not often found in the endemic regions. Furthermore, 
this method is a lot more expensive due to the primers needed and the laboratory 
equipment (Cook et al., 2015). It is however an effective method to determine the 
species of Plasmodium.  
As malaria is still a dominant global concern, with a 92% mortality rate in Africa (Tambo 
et al., 2018) new, affordable diagnostic techniques are a constant priority. A recently 
new alternative to PCR, Loop mediated isothermal amplification (LAMP) provides a 
rapid result with sensitivities as good as PCR itself, giving a more accurate reading 
than the leading RDTs. PCR works using a thermo-cycler that amplifies DNA at many 
different temperature’s in order to anneal and denature the parasites DNA, detecting 
parasitaemia as low as 1-2parasites/μL. While LAMP uses a stable constant 
21 
 
temperature through at 65°C while detecting parasitaemia at the same volume (Tambo 
et al., 2018). LAMP diagnostic is also available to be conducted in the field making it 
much more beneficial to detecting patient malaria (Hopkins et al., 2013). 
 
1.6 Vector control  
 
Vector control is potentially the most important step in combatting malaria outside 
effective antimalarial chemotherapy. If there were no vectors to transmit the parasite, 
the death burden will fall. However eradicating mosquitoes would be an impossible 
task so controlling them is key. Vector control comes in the forms chemical, biological 
and mechanical, however, all are still to be perfected.  
Chemical insecticides (chemical control) are currently the most used deterrent in 
combatting malaria (Glunt et al., 2013). The most effective and successful chemical 
deterrents are indoor residual sprays, along with insecticide treated bed nets (ITNs), 
long-lasting ITNs and spraying other materials such as furniture and clothing. Using 
these basic control methods especially at night time when mosquitoes usually feed, it 
can help stop malaria upon impact (Kamareddine, 2012; Glunt et al., 2013; 
Raghavendra et al., 2011). The spraying of pesticides directly upon the roofs and 
walls, along with insecticide fogging is also effective in combating female mosquitos. 
This method decreases the life span that the mosquito would naturally has, thus 
limiting contact with humans (Raghavendra et al., 2011). 
The chemicals used in the above chemical insecticides are pyrethroids. These are 
commonly used due to the low toxicity levels that are deemed safe for human use 
(Childs et al., 2016). Chemicals used in the past however have not always been safe 
for human use or beneficial to the environment. Dichlorodiphenyltrichloroethane (DDT) 
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was introduced in the twentieth century, leading to a new era of insect control 
(Raghavendra et al., 2011). DDT was highly efficient, leading to the eradication of 
malaria from Europe and was the first major insecticide used in vector control. 
Irrespective to DDTs success it was later banned by the Environment Protection 
Agency (EPA). Due to the negative environmental impacts it alongside an association 
with causing cancers including breast cancer in humans (Raghavendra et al., 2011; 
Kamareddine, 2012).     
Larval control is a biological form of vector control. Larvicides are a proven malaria 
preventative but is somehow overlooked and not implemented. The aim of larviciding 
is to eradicate or dramatically reduce the number of vectors in known larval infested 
waters, before they mature into adults and become mobile. However, there are 
thousands of habitable places where larvae can live in a given country, therefore 
larviciding every one of them could lead to many different ecological problems. 
Larvivorous fish have been introduced in many countries in a bid to reduce adult 
populations, however chemical larvicides such as Paris green (copper acetoarsenite) 
have been banned due to high levels of arsenic (Raghavendra et al., 2011).   
There are two known species of bacteria that have been proven to be biological 
larvicides. Bacillus thuringiensis israelensis (Bti) and Bacillus sphaericus (Bs) 
(Kamareddine, 2012). Both Bti and Bs work by poisoning the mosquitoes mid gut 
causing the cell membranes to break down, eventually killing the mosquito (Ingabire 
et al., 2017). These biological larvicides are beneficial as they have no effects on 
humans but have been known to affect amphibious life (Raghavendra et al., 2011).  
The use of entomopathogenic fungus as an alternative to bacterial vector control has 
also been used. Fungal species in genera such as Lagenidium have been studied as 
a disease control. The benefit of using fungus, is that the fungus itself does not need 
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to be injected into the vector. Cuticle contact is efficient enough to infect. This method 
can be applied in and around larval habitats and around the homes and work places 
of them in high-risk areas (Kamareddine, 2012). 
Biological control can be increased in the form of introducing transgenic mosquitoes 
(sterile males) into the atmosphere to compete with fertile males. Decreasing the 
population can also be effective and has been considered as a vector control strategy 
(Knols et al., 2007; Kamareddine, 2012). Genetic engineering of the transgenic 
mosquitoes could also be a vector control by altering the DNA with foreign DNA to 
possess anti-parasite macromolecules limiting malaria transmission (Kamareddine, 
2012).  
Mechanical control involves physically removing a breeding ground in order to destroy 
the habitat mosquitoes use to breed and grow as larvae. This could involve the 
removal of eutrophic waterbodies. The removal of the stagnant water bodies such a 
lakes, canals and ponds would limit the mosquitoes surface area. Simple strategies 
involving removing man-made objects that could collect rain water could also be an 
effective way to mechanically control the vectors (Lindblade et al., 2015).  
Personal protection is an important form of vector control, preventing the bite taking 
place initially significantly decreases the chance of malaria transmission. This can be 
achieved by applying repellent oils, creams and sprays such as DEET. However, in 
many developing countries such items would be classed as a luxury. products would 
not be easily affordable, especially when they are only effective for several hours after 
application. Some countries prefer to use natural products as alternatives such as 
eucalyptus.  
Malaria vaccinations are not a form of vector control, however, currently RTS,S/AS01 
are the most advanced vaccinations to date in combatting  P. falciparum. Stage 3 trials 
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finished back in 2009 in several countries in sub-Saharan Africa. This vaccine is 
currently up for stage 4 evaluation. There are also 20 other vaccines currently being 
researched (WHO, 2019).    
1.7 History of antimalarial drugs  
1.7.1 Quinine  
 
Quinine is classified as one of the most ground-breaking discoveries of the 17th 
century. Quinine remains an important antimalarial 400 years after being discovered 
in the 1600s (Cui et al., 2013). Quinine is a natural product that is derived from the 
Cinchona tree and was originally referred to as the “sacred bark”, the name originating 
in 1630 from Jesuit missionaries. There was, however, an earlier legend of quinine 
use that derived from an Indian who had found himself lost in a jungle located in the 
Peruvian Andes. The person with high fever had taken a drink from a stagnant pool 
that had been in contact with the surrounding cinchona trees. After initially thinking 
they had been poisoned, the fever disappeared. This new “fever cure” was shared with 
local villagers who eventually used the trees bark to cure their fevers (Achan, Talisuna 
et al., 2011). 
Quinine was introduced to Europe after a Spanish Countess contracted a fever while 
in Peru. She was later cured after being administered bark from the tree, giving it the 
new name ‘countess’s bark’. The bark was then taken back to Spain, introducing 
Quinine to Europe in 1638 (Achan, Talisuna et al., 2011). The powdered bark was 
then added to drinks such as wine and taken orally (Achan, Talisuna et al., 2011; 
Fluckiger & Hanbury, 1874). Before being taken back to Europe it was common for 
Europeans to use European and Asiatic plants as fever remedies (Stuart, 2004).   
Quinine was later promoted by Cardinal de Lugo, the Procurator General of the order 
of the Jesuits. The Jesuits then seized the opportunity and made profit by controlling 
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the entire supply of bark into the west, thus changing its name to ‘Jesuits bark’. Due 
to this demand, native trees became threatened and numbers started to decline. This 
resulted in the need for cultivation and the Spanish doctor, Jose Celestion Bruno Mutis 
started this initiative (Stuart, 2004).  
During the 1820s, a couple of well renowned French pharmacists were able to isolate 
an alkaloid from the plant that they named quinine (Stuart 2004). Quinine is a cinchona 
alkaloid belonging to the aryl amino alcohol group of drugs (Achan, Talisuna et al., 
2011). 
Quinine was the most commonly used antimalarial up until the 1920s, after this there 
were just as, if not more, effective synthetic antimalarials available on the market such 
as chloroquine and amodiaquine (Mojab, 2012), The most important of these was 
chloroquine (Achan, Talisuna et al., 2011). 
Mefloquine was first introduced in the 1970s and is an antimalarial that is phospholipid 
interacting. It is effective against mild to moderate P. falciparum infections. Mefloquine 
is active against the parasites erythrocytic stage, however it is ineffective during the 
hepatic stage. This drug works buy enlarging the parasites food vacuole, in turn 
damaging the haem which destroys the membrane. Mefloquine is typically used as a 
prophylaxis, before travel and for several weeks after infection is suspected and works 
well with chloroquine-resistant strains of P. falciparum.  
1.7.2 4-Aminoquinolines (Chloroquine, Amodiaquine and Piperaquine) 
 
Chloroquine is an antimalarial that is part of the 4-aminiquinolines drug group. In 1934, 
research by a group of scientists, including Hans Anderson led to the discovery of a 
new synthetic substitute for quinine named chloroquine, along with a 3-methyl 
chloroquine (Lei et al., 2020). These new antimalarial compounds were however 
deemed toxic and the German research went no further. The formula was passed onto 
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a United States of America company after French soldiers found the German protocols 
on how it was to be made (Bhattacharjee, 2016). 
The United States government made slight adjustments during World War II and 
entered the captured drug into clinical trials in 1947, as a prophylactic treatment of the 
malaria parasite (Bhattacharjee, 2016).  Chloroquine in its heyday was classed as 
revolutionary, mainly due to the efficacy and safety (even during pregnancy) along 
with affordability (Baird, 2005; Karagoz et al., 2018). Chloroquine was typically used 
to treat all human Plasmodium strains, however, use on P. falciparum became more 
restricted after the 1950s. This was due to resistant strains arising in 3 separate 
regions simultaneously in Southeast Asia, Oceania, and South America.  
Chloroquine was discovered to work by inhibiting the haem detoxification process. The 
mechanism by which it works involves drug concentrations that reach 1000-fold within 
the acidic food vacuole found within the parasite which in return results in parasite 
elimination. As chloroquine is positively charged, it is able to accumulate due to the 
charge being repelled by the vacuole membranes positive charge. After this 
chloroquine is able to accumulate, resulting in a build-up of haem. The increased build 
up then proves fatal to the parasite (Takala-Harrison & Laufer, 2015; Slater, 1993)  
Amodiaquine is structurally related to chloroquine and was synthesised in 1948 (Whirl-
Carrillo et al.,2012). However, it has been deemed toxic too for use alone, and is 
usually used in partnership with piperaquine (Cui et al., 2013). Amodiaquine has links 
to causing severe hepatitis, leading to fatalities and is recommended for treating 
malaria but not prophylaxis (Adjei et al., 2009). The compound also shows inhibition 
of the malarial heme detoxification pathway leading to a build-up of ferriprotoporphyrin 




Piperaquine was synthesised in China during the 1960s, and has seen been used 
heavily across both China and Indochina for prophylaxis and treatment of malaria. 
Studies in these countries have shown the drug to be just as effective and well 
tolerated as chloroquine for the treatment of P. falciparum and P. vivax. Piperaquine 
(Davies et al 2005). The use of piperaquine dropped during the 1980s after resistant 
strains of P. falciparum emerged. More recently, China has developed a piperaquine 
combination with artemisinin to combat the resistant strains.    
1.7.3 8-Aminoquinolines (Primaquine) 
 
Primaquine is currently the only potent gametocidal drug commercially available on 
the market to date, showing positive results in the use against P. falciparum. Due to 
its activity against hypnozoites, the drug is administered orally to hinder relapses of P. 
ovale and P. vivax once a completed treatment of blood schizonticide has had it full 
course (Ashley et al., 2014). Primaquine is also used to prevent re-infection to those 
who are returning to potentially high-risk areas. Once the malaria parasite breaks 
down the haemoglobin into two parts the haem and globin, the haem becomes toxic 
towards the parasite. Plasmodium produces a chemical that converts the haem into a 
non-toxic form enabling its survival. This drug has an adverse effect upon the 
mitochondria. This depletes the parasite of energy blocking the release of the haem, 
changing chemical, and thus killing the parasite due to the build-up of toxic haem. 
Primaquine is not classed as a prevention drug and is usually a 7-day course that is 
used alongside Artemisinin-based combination therapy ACT or chloroquine (Bray et 
al., 2005). 




Antifolates are a class of compounds known to antagonise the folic acid folate 
pathways, thus restricting parasite DNA synthesis (Visentin et al., 2012; Desai et al., 
2016). Sulfadoxine-pyrimethamine is the most used drug to combat P. falciparum 
strains that have developed a resistance to chloroquine in certain regions (Kublin et 
al., 2002). When chloroquine was still the first drug of choice due to low levels of 
resistant strains being present, Sulfadoxine pyrimethamine was usually the second 
drug in line for treatment (Kublin et al., 2002). The mode of action involves the pair 
working in synergistically to prevent two enzymes that are needed for the folate 
biosynthetic pathway. Sulfadoxine and dapsone work by inhibiting the dihydropteroate 
synthetase enzyme that is found within the parasite’s folate pathway. Pyrimethamine 
and dapsone work by stopping the dihydrofolate reductase within the thymidylate 
enzyme (Hayton & Su., 2008). These drugs in partnership prevent Plasmodium 
reproduction as well as growth (Gatton et al., 2004; Cui et al., 2013). Synthesis of 
tetrahydrofolate is stopped by sulfadoxine working against p-aminobenzoic acid at the 




Figure 1.3 Chemical structures of know antimalarial drugs discoveries. Showing the chemical 
structures of Some of the better-known antimalarials are dating between 1820-1980. Some drugs such 
as chloroquine are still in use to date, while some deemed ineffective due to parasite resistance. The 
dates shown within the brackets indicate resistance (Source Edwin et al., 2019). 
1.7.5 Artemisinins and Artemisinin-based combination therapy (ACT) 
 
Artemisinin is a naturally derived product from the sweet woodworm plant (Artemisia 
annua) and originated from China. Upon its discovery it was hailed as one of the best 
medical discoveries of the 20th century (Krishna et al., 2008). Artemisinin is the first 
line drug of choice for treatment of P. falciparum for uncomplicated malaria (Su et al., 
2015) Artemisinin is considered to be highly active and fast-acting against multiple 
parasites and at different development stages (Visser et al., 2014). The compound is 
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highly effective at lowering the transmission rate of malaria as it has the ability to 
destroy immature and developing gametocyte, thus lowering the chance of a mosquito 
contracting the parasite in a blood meal (Okell et al., 2008). The drug’s activity is not 
however fully understood but it is thought to have its toxicity due to the haem-mediated 
decomposition located within the endoperoxide bridge, producing carbon-centred free 
radicles (Petersen et al., 2011).  
Artemisinin-based combination therapy is considered to be the best current treatment 
for malaria. It uses two separate drugs working at the same time to ensure effective 
treatment. It works by combining artemisinin with partner drugs that include 
sulfadoxine-pyrimethamine for severe malaria (Cui et al., 2013) and drugs such as 
amodiaquine, lumefantrine and mefloquine (as mentioned above). Artemisinin works 
rapidly killing off the majority of parasites within the blood, while the partner drug works 
a lot slower, this prevents resistant strains developing to the compounds while 
dramatically lowering the transition rate (Visser et al., 2014). 
1.7.6 Antibiotics  
 
Antibiotics as treatment for malaria are recommended as they are universally already 
available and have passed multiple trails already making them a very cost-effective 
treatment and prevention for malaria when traveling to countries with a high 
transmission rate. Antibiotics used as antimalarials include doxycycline, clindamycin 
and tetracycline. These drugs are extremely useful in countries that have a high level 
of resistant strains to drugs like chloroquine. The downside, however, is that such 
antibiotics can have adverse side effects to people taking them such as limiting the 
amount of sun exposure a person can have, given they are in countries with extremely 
high temperatures (Tan et al., 2011). Furthermore, the use of these drugs would 
deprive their usage as anti-microbials, where drug shortages exist already. 
31 
 
Tetracycline is used to treat children who are not old enough to have other treatments. 
Doxycycline is commonly used alongside quinine and is effective for treatment for 
complicated P. falciparum infection. Clindamycin is used alongside quinine too; 
however, it is used when the infection of P. falciparum is acute and has limitations on 
children.  
1.8 Drug resistance  
 
The problem with Plasmodium parasites and why they are so difficult to eradicate via 
drug treatment is down to the parasite being genetically diverse. When the parasite 
passes through the mosquito vector they reproduce, and like any other reproducing 
organism exchange pieces of their DNA. This exchange of DNA results in mutations. 
These mutations enable the parasites to evade drugs and spread at a much faster 
rate, due to the parasite becoming less sensitive to the family of drugs (Hayton & Su., 
2008).   
As chemotherapy has been the front-line combat in the control of malaria, resistant 
strains of Plasmodium have become the biggest threat to malaria treatment. With all 
the commonly used malaria medications including artemisinin developing resistance, 
the need for new drugs is a top priority project (Ashley et al., 2014). With mutations 
being the biggest threat to resistant strains, it is important to understand that some 
drugs such as chloroquine requires one single mutation to develop resistance, while 
others may require several and this can lead to many more complications in battling 
drug resistance (Mohammed et al., 2013). When drugs focus on specific inhibitors that 
are highly potent, this means they have a specific target that can mutate and mutate 
quite quickly. The main mechanism used to overcome this is the advocacy of 
combination therapy with multiple modes of action, as practiced with ACT.  
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Drug resistance has been a battle for several decades. It has been observed that drug 
resistance often emerges in the same geographical locations such as Asia. 
Chloroquine, mefloquine, quinine, pyrimethamine and now artemisinins have all 
developed drug resistance in South East Asia. The resistant Plasmodium have since 
spread across to Africa as a result of a mutation directly linked to Asia (Price et al., 
2004). Not all mutations have been directly linked to Asia, in sub-Saharan Africa. For 
artimisinins, the current frontline drug, a K13 propeller mutation was discovered in P. 
falciparum, which Is still yet to enter Asia (Fairhurst and Dondrop 2016). Kelch is a 
gene located on chromosome 13, the discovery of this gene gives hopes in detecting 
early the development of artemisinin resistance. Discovering the K13 marker will 
enable to scientist to locate resistance more quickly, avoiding a public health disaster 
such as what happened with chloroquine. 
1.8.1 Chloroquine resistance  
 
Chloroquine resistance in P. falciparum emerged from Cambodia in 1960, however 
failures with the drug had been happening over several years prior (Batista et al., 2009; 
Najera et al., 2011). In South America resistance emerged in 1959. This however, was 
an independent development of resistance and was not connected to the mutation in 
South East Asia (Dondrop et al., 2010). From Asia the resistant strain spread to East 
Africa and was reported there in 1978, and by 1988 chloroquine resistance had spread 
across all tropical countries in Africa resulting in over three million deaths (Mohammed 
et al., 2013).  
Resistance to chloroquine caused by the mutation of two separate genes that are both 
located within the food vacuole. The resistant mechanism involves doubling up a reflux 
pump that is coded by the P. falciparum chloroquine resistance transporter (pfcrt) 
gene. This mutation means that when chloroquine enters the parasite’s food vacuole 
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it is immediately excreted. The second gene mutation is P. falciparum multidrug 
resistance transporter-1 (pfmdr-1) this works the same way but by mutations of 
D1246Y, N86Y, S1034C and N1042D to remove chloroquine from the food vacuole 
(Mohammed et al., 2013; Koenderink et al., 2010). Resistance is caused by a single 
amino acid mutation from pfcrt that causes lysine to be replaced by threonine. This 
change results in the once positively-charged lysine to change to a neutral threonine 
impacting the vacuole. Due to this mutation, chloroquine is unable to concentrate in 
the food vacuole and block the conversion of toxic heme to inert haemozoin pigment, 
resulting in a loss of effectivity on the Plasmodium parasite (Mohammed et al 2013).  
1.8.2 Antifolate resistance  
 
At first pyrimethamine was used as an antimalarial on its own, however after only one 
year of use resistance was seen in P. vivax and P. falciparum and so sulfadoxine-
pyrimethamine came into use (Cui et al., 2015). The significant rise of sulfadoxine-
pyrimethamine resistance was reported in 1981 (Hurwitz et al., 1981), although early 
reports of resistance were observed in Thailand and Cambodia as early as the 1960s 
(Petersen et al., 2011). Regions such as Africa and South East Asia are more heavily 
affected by the resistant strains than any regions (Braid, 2005). As these drugs act by 
interference with the folate pathway, mutations in this pathway are the main cause of 
resistance. The antifolate drugs are effective agents in prophylaxis and therapeutics 
and they can also be used in combination where they act synergistically (Gregson & 
Plowe, 2005). 
Resistance to these classes of drugs have however arisen, primarily due to point 
mutations in the dihydropteroate synthase (DHPS) and the dihydrofolate reductase 
(DHFR) genes. These are the two main enzymes that are responsible for the folate 
biosynthetic pathway targeted by the antifolates (Gregson & Plowe, 2005). However, 
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it is still the first front-line drug of action in some parts of sub-Saharan Africa as a safe 
and cost-effective alternative to chloroquine when resistance to that is high. 
Once resistance to a drug has developed in a certain region it is then removed as a 
treatment for malaria and replaced with another, there is evidence re-introduction of 
the drug after several years can restore sensitivity. An example of this is in Malawi, 
where chloroquine resistance was discovered. After 12 years of the drug being 
discontinued, resistance to the drug lowered and in 2006 the drug was reinstated as 
an effective treatment for malaria (Laufer et al., 2006) 
1.8.3 Quinine and Mefloquine resistance  
 
Quinine resistance first became apparent in Brazil and then was later found in South 
east Asia. Resistance is currently found within the Western and South-East Oceania 
area, however, is less frequent in Africa (Schlitzer, 2008).  Resistance to quinine was 
shown to be caused as a result of multiple gene mutations, classifying this resistance 
as complex (Peterson et al., 2011). Quinine resistance is heavily associated with 
polymorphisms in the parasite’s drug transporters pfmrp1, pfcrt and pfmdr1. Studies 
based on the relationship between polymorphisms and pfnhe1 for parasite sensitivity 
to quinine have proven to be inconsistent in the results. However, most test have 
shown that the multiple polymorphisms are having an impact on the parasite sensitivity 
to the drug (Cui et al., 2015).  
Mefloquine was introduced in Thailand during 1984 and was successful upon 
introduction. After 6 years of being a front-line choice of medication, resistant strains 
were reported even after careful administration and stringent regulations to avoid such 
a thing happening (Price., et al 2004). As resistance arose in Asia, it led to the 
resistance of halofantrine alongside with quinine. As resistance grew in Thailand, it 
also spread to neighbouring countries such as Cambodia and Burma (Hayton & Su, 
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2008). Due to resistance to mefloquine appearing it has since been used alongside 
artemisinin as a combination therapy and has since proven to be an effective form of 
treatment, however resistance along the Thailand-Cambodia border has been noted 
to this combination too (Price et al, 2004). 
1.8.4 Artemisinin resistance  
 
Artemisinins are classed as an indispensable and frontline drug in the use for malaria 
treatment. The increased resistance has revived worldwide attention due to the 
importance of the drug’s ability at combating the disease. In Thailand and Cambodia 
where antimalarial resistant strains are documented already, overuse and misuse of 
medications may have a role to play in resistance development (Dondorp et al., 2010). 
Artemisinin and mefloquine resistance are primarily documented along the Thai-
Cambodian border. After anecdotal observations, studies documenting treatment 
failure were reported in 2008 (Cui et al., 2015). According to the WHO, resistance to 
artemisinin has now been documented in several different countries including 
Vietnam, Laos and Myanmar.  
 
Several genome studies in P. falciparum have shown there is a mutation in regions on 
chromosome 13, which has been directly linked to reduced parasite clearance 
following artemisinin treatment. When treatment involves combined drug treatment, 
with a genomic approach, mutations inside the propeller domain were identified in the 
kelch 13 gene PF3D7_1343700 (K13) in late 2013 (Cui et al.,2015).  
In the studies in Africa, the K13 gene polymorphisms are highly present in the 
mutation-prone propeller domain. In Asia however, such mutations are yet to be seen. 
When a parasite has a K13 mutation, it appears to show a higher rate of survival after 
a dihydroartemisinin pulse, this is then used to determine the level of resistance the 
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parasite has acquired. When the parasites had developed this resistance, they are 
also shown to have had increased expression of response pathways. With unfolded 
pathways and also ring stages that were considerably long-lasting (Cui et al., 2015). 
1.8.5 Insecticide resistance. 
 
The mosquitos themselves are becoming genetically resistant to some of the current 
insecticides used to control the vectors. The resistance is thought to be spreading at 
a rapid rate. It is thought that long-lasting insecticide-treated nets (LLINs) and indoor 
residue sprays (IRS) programs are the main reason for the emergence of insecticide 
resistant strains of mosquito being present in the environment (Childs et al., 2016). 
1.9 Current antimalarial drugs  
 
Antimalarial drugs combat the erythrocytic stage of the parasite which results in the 
parasite being eliminated from the body (Cui, et al., 2013). Artemisinins are still 
considered to be the current front-line treatment due to the potency they have on the 
parasite (Fairhurst Dondrop, 2016). Artemisinin is a leading current drug due to its 
efficiency in targeting all blood stages of the parasite. impacting ring, trophozoites and 
schizonts stages. It is also an effective gametocidal drug thereby ensure the blocking 
of transmission of the infection to the mosquito vector. This drug alone, however, does 
not have an impact on the merozoites and mature gametocytes in the parasite’s life 
span (Fairhurst & Dondrop, 2016) 
ACTs are currently used alongside the 8-aminoquinolines and the 4- aminoquinolines 
as recommended by WHO, to treat P. falciparum in high prevalence areas and are 
currently one of the most effective drugs for the treatment for all stages of the parasite. 
ACTs that are currently recommended and currently in use are 
artesunate/sulfadoxine-pyrimethamine, artesunate/ amodiaquine, 
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dihydroartemisinin/piperaquine, artesunate/ mefloquine, artemether/ lumefantrine and 
artesunate/ pyronaridine (Cui, et al 2013) 
1.10 New antimalarial drugs  
With the Plasmodium parasite’s ability to evolve and develop resistance to every drug 
that has been developed, the need to discover create new drugs to combat the disease 
is more important now than ever. Research and drug development require several 
approaches to develop an effective finished product, that will tackle the malaria burden 
(Gamo, 2014). Denovo drug discovery refers to the discovery of new therapeutic leads 
(synthetic and natural product) as effective antimalarials. Another way in which drugs 
are developed is drug repositioning or repurposing, where drugs that have been 
proven to treat other diseases, for example cancers are screened against malaria, with 
the singular advantage of shortening the drug discovery pipeline. Another way is to 
reintroduce an old drug that has in the past been considered to be ineffective in the 
fight against malaria, to see if resistance has passed. Despite enormous financial 
investment, the search for a safe, effective and affordable antimalarial continues to be 
an elusive challenge (Hobbs & Duffy, 2001). 
1.10.1 Semi-synthetic drugs  
 
Semi-synthetic drugs that have been developed as derivatives of an effective parent 
compound, e.g. chloroquine from quinine, or artesunate and artemether. Drug 
resistance has also forged an interest in a novel series of synthetic peroxides that can 
be used as a new treatment against malaria (Marti et al., 2011). Compounds such as 
ozonide belong to a group of a synthetic trioxolane by-products. This compound Is one 
of the leading examples of synthetic endoperoxides undergoing research and testing 
to become a new synthetic antimalarial drug treatment. There have been several 
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studies on this possible new drug with in vivo animals trials showing improved oral 
bioavailability while possessing a prolonged half-life (Marti et al., 2011). When 
compared to other synthetic drugs derived from artemisinin, this new group is relatively 
low cost, efficient and shown to have improved biopharmaceutical properties 
(Griesbeck et al., 2017: Perry et al., 2006). 
1.10.2 Pharmacophore hybridisation  
 
A new approach in the development of new drugs incudes pharmacophore 
hybridisation. This new possibility of developing new antimalarial compounds by 
hybridisation is an exciting approach that involves the combination of pharmacophore 
compounds. When the compounds that are due to be combined possess different 
groups from different mechanisms of action, this can be an extremely effective way to 
avoid resistance in the future (Ginsberg & Deharo, 2011; Guantai et al., 2012). In a 
study by Dechy-Cabaret et al (2000) it was shown that when 1,2,3,4-triozane was 
covalently linked to a 4- aminoquinoline compound through an adequate spacer, 
promisingly active trioxaquines had been developed. When the study on trioxaquine-
4-aminoquinoline was performed upon three different drug resistant strains of P. 
falciparum the compounds were shown to be highly effective. The IC50s revealed from 
the study were between 2-86μM, showing effective results (Dechy-Cabaret et al., 
2000) increasing expectations that this new hybrid option will produce a new novel 
drug.  However, from evidence from recent studies indicates that the previously 
reported advantages of these hybrids such as low toxicity, simple formulations and 
improved pharmacokinetics have still to be proven and realised. In order for this new 
method to be passed into clinical development and late clinical trials a number of 
unanswered questions will have to be addressed before these new drugs are deemed 
of worth to the investors (Agarwal et al, 2017) 
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1.10.3 Protease inhibitor drugs  
 
There are a number of drugs that fall into a group called protease inhibitor drugs which 
are used in the treatment of human immunodeficiency virus (HIV). Some of these 
drugs have been known to possess anti-parasitic properties. Some of these drugs 
include lopinavir, atazanavir and saquinavir (Lek-Uthai et al., 2008).  During in vitro 
studies on human malaria parasites, protease inhibitor drugs have been shown to 
have fatal effects upon P. falciparum’s erythrocytic stages. This method however, is 
not always an effective method for patients who are already immunodeficient as it 
could interfere with their current treatment. Antimalarials can also have an impact on 
the level of medication found within the blood of a patient who is already taking HIV 
medication (A Fehintola et al., 2011). In animal studies however, a species named P. 
chabaudi, which is a known rodent plasmodium was also shown to have an impacted 
erythrocytic stage after being exposed to protease inhibitor drugs in vitro (Hobbs & 
Duffy, 2011; Lek-Uthai et al., 2008)  
1.10.4 Antibiotics  
 
As previously mentioned, antibiotics have been known to possess antimalarial 
properties, however only certain classes of antibiotics have these properties. Classes 
such as macrolides, tetracyclines and lincosamides have the potential antimalarial 
properties that can be used to treat patients (Gaillard et al., 2016). The antibiotic mode 
of mechanism usually works by affecting a primitive part of the plasmodium’s target 
pathways in the apoplast. (Noedl,2009). As discussed, the use of antibiotics is 
favourable as they are easily accessible and approved for human consumption (Tan 
et al., 2011; Gaillard et al., 2016). Until recently, antibiotic treatment for infections 
caused by P. falciparum was thought to be ineffective. Now, however, they are 
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deemed useful in conjunction with a partner drug that has known antimalarial 
properties (Pradel & Schlitzerr, 2010; Gaillard et al., 2016).  
Antimalarials such as quinine, used alongside antibiotics such as doxycycline and 
tetracycline can have a positive impact on patient recovery.  These drugs constitute 
the most common form of antibiotic combination therapy. Due to the success of this 
combination therapy, it has been used in South East Asia extremely successfully as a 
second line treatment (Gaillard et al., 2016). Quinine/ antibiotic therapy also has some 
down sides as it has some unpleasant side effects including nausea, headaches and 
abdominal pain. When new antibiotics are discovered, testing them alongside 
antimalarials in the future could bring new treatment opportunities (Song et al., 2016) 
1.10.5 Anti-cancer agents  
 
Anti-cancer agents such as methotrexate and trimetrexate are becoming an extremely 
popular topic of research as antimalarial drugs, with many repositioning trials showing 
shared effectivity in the two diseases. Recent studies have shown synergistic activity 
when anticancer drugs are used alongside artemisinin (Das, 2015). It has been 
discovered that these drugs have a double mode of action on the parasite. Both drugs 
will work together to damage the proteins that are found within the proteasome, in time 
building up and blocking the waste disposal system of the parasite. The hope for this 
possible new combination therapy is that it will also evade resistance by acting quickly 
while remaining within the bloodstream for quite some time.  
Anti-cancer agents such as methotrexate and trimetrexate that been found to be 
extremely active again malaria. The problem these type of compounds presents is that 
they are deemed to toxic to use, therefore using them as an antimalarial at the moment 
is not possible. Further studies are needed in order to fully understand mechanism of 
action and dosages needed for ultimate response. The toxicity of anti-cancer drugs 
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can be lowered when the dosage is lowered, novel combination therapies with 





Figure 1.4. Potential drug targets. showing the intraerythrocytic plasmodium parasite and the 
potential targets new drugs can be directed towards to be to successful antimalarials (Source 
Greenwood et al., 2008) 
1.11 The Drug discovery process  
The traditional drug discovery process is extremely time-consuming and costly, in 
some cases the price exceeds $1 billon. The reason behind such a price tag and length 
of time is due to the number of compounds that enter the research and development 
sector. The high attrition rate implies that if for example, 10000 compounds that go 
through such research and development, only one compound will be worthy of ending 
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up as a consumer product. The original compound/ idea usually derives from 
universities or clinical and commercial sectors in a given field. With malaria, there is a 
high demand currently for antimalarials that impact the blood stages of the parasite to 
alleviate the symptoms. New drugs aimed at the liver and transition stages are in their 
early days, but highly desirable. Lead compounds with gametocytic activity are crucial 
to ensure blocking of transmission of the disease to the mosquito vector. When these 
drugs are put through tests, they must meet multiple stringent criteria to be classed as 
an effective antimalarial.  New drugs need to be extremely fast acting, ensuring the 
disease does not progress. The new drugs must be safe for use in pregnant/ Brest 
feeding women, children and ideally involve one dose in the overall treatment. Due to 
such high costs relating to the research and development sector, many companies 
and organisations are not willing to fund such research and trials, due to the risk of it 
not being economically viable. The Bill and Melinda Gates foundation, however, have 
displayed an interest in the development of new antimalarials in addition to funding the 




Figure 1.5 Drug discovery process showing the number of compounds that pass each stage of 
development along with the time scale it takes for each. (Redrawn from Trends in drug discovery and 
pharmaceutical research, 2002). 
The main sectors behind drug development are academia and pharmaceutical 
companies. There are different ways a drug can be developed and these include 
random drug screenings of synthetic or natural product compounds, rational drug 
design and repositioning or re-purposing of old/existing drugs. The sequencing of the 
genome of the human body along with the genome of P. falciparum has resulted in an 
era with many more opportunities for drug development and related research. 
Genomics platforms along with bioinformatics have contributed to broadening options 
for drug discovery, rekindling hope that eradication of malaria in the future could 





1.11.1 Random screening of compounds  
 
The random screening of compounds is a screening method that works by large 
libraries of compounds being used in screening assays against disease targets. This 
method uses high throughput screening and this is the typical starting point usually in 
the drug discovery timeline. It involves large libraries of compounds (natural and 
synthetic) alongside high throughput automated platforms and sophisticated software 
options for data analysis. A high number of drugs used on the market today have come 
about through random screening of these large libraries. Compounds within the library 
can be flexible and come from either chemically synthesised compounds or ones that 
have been derived from a natural product which is the focus of this thesis.  
1.11.2 Rational drug design  
 
This method involves design using computer modelling that predicts binding to 
proposed targets, to inform in vitro testing on parasite lines. For rational design to be 
implemented, x-ray crystallographic 3D structures of target proteins need to be 
available. Leads, once tested in the preliminary in vitro setting are then into 
pharmacokinetic, pharmacodynamic and toxicity testing (ADMETox), prior to in vivo 
testing on animal models and subsequently humans before they are deemed safe to 
use. Both screening and rational design are extremely time consuming and expensive 
with many compounds not passing the stringent test stages (Aguero et al., 2008).  
  
1.12 Natural Products 




Natural compounds that have been extracted from any natural object, but mostly 
plants, have been used in traditional medicine for thousands of years. Plants have 
been used throughout history to prevent and cure a number of deadly infectious 
diseases. Primitive ancestors observed their natural surroundings and learnt to study 
the land and the animals around them over time, and through much trial and error, this 
led to the development of some of the medical plants that are still in use today. 
Palaeontology studies recoded in ancient Iraq indicate that Neanderthals possessed 
knowledge of plants with medical properties dating back to 60,000 B.C (Lietava, 1992; 
Ji et al., 2009) Compounds from plants that possess medical benefits have been 
described on ancient Assyrian tablets that date as far back as 2000 B.C.  They have 
also been inscribed in ancient Egyptian hieroglyphics, and mentioned in ancient 
Indian, Chinese and European documents through history (Deharo & Ginsburg, 2011).  
In 2004 there were over 1,277 plants and 160 plant families that were commonly being 
used as traditional medicines to treat malaria alone. Since 2004 there has been 
extensive studies into many more natural products, increasing this number 
significantly, due to an increased interest in malaria research world-wide, especially in 
anti-malarial plants (Rasoanaivo et al 2011). There is a huge interest in antimalarials 
derived from natural products due to two of the leading malaria treatments quinine and 
artemisinin being able to trace their origin back to the use of traditional medicines 
(Graz et al., 2011). 
In rural areas in developing countries traditional medicines are often the only from of 
treatments that are generally trusted and accepted amongst communities. For these 
types of communities this is often the only source of treatment that can be accessed 
and afforded as they can be made locally for a fraction of the price of pharmaceuticals. 
People across the planet choose to use traditional medicines for many reasons, some 
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of them being: living in enclosed, remote areas where access to modern medical care 
is limited and traditional medicines are the first choice. Others choose traditional 
medicines because they believe they simply work better and have lost faith in the 
health care systems of the country they reside in. Fake drugs and side effects can add 
to the general mistrust in the Western medical systems (Bertrand et al., 2011). Some 
in India and in many places in China, still practice the study of ancient traditional 
medicines, where ancient techniques have been turned into new practises such as 
homeopathy, however it is important to understand that these practises have not been 
validated officially (Graz et al., 2011).  
Many modern medicines derived are from a natural products, WHO records indicate 
that 74% of current drugs have a natural product origin. Many industrialized countries 
are increasing their usage of natural products in everyday life, a prime example of this 
would be naturopathy. Many natural products do however, have a downside, the main 
one being that many herbs and plants have not been through extensive scientific tests 
and clinical trials to determine the plant’s effectiveness (Graz et al., 2011).  
In recent times it is becoming crucial to understand and evaluate the properties of 
natural products given that 75% of the world’s population is heavily dependent on their 
use in clinical and traditional settings (Global monitoring report, 2018). 
Today most companies within the pharmaceutical industry are under immense 
pressure for new drugs to be available on the market. Complex discovery pipelines 
mean that the pharmaceutical industry faces significant challenges such as cost and 
time. Pharmaceutical companies today face challenges around sustainability. The cost 
of research and development has risen significantly since the 1980s costing up to $40 
billion dollars, however, there has been no correlation between new drugs available 
and to the rising costs. With research and development prices exploding, companies 
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are searching for new approaches to drug design. Traditional medicines are becoming 
an attractive approach in relation to natural-based drug discoveries as drug discovery 
is not solely based entirely on molecular entities (Hagai & Eric, 2011; Timothy, 2011). 
A drug that has been rationally designed, standardized and tested scientifically 
deriving from natural products is named a phytodrug. They could potentially provide 
safer alternatives to chemically created treatments. The WHO has recognised this and 
has since created the Traditional Medicine Program (TMP). This program researches 
the use of traditional medicines from across the world, taking note of good and bad 
practice in order to establish useful scientific information to enable a safe dosing 
system of each natural medicine. The TMP also acknowledged that the role of 
traditional medicines for drug development is a reliable and sustainable solution for 
the health care industry (WHO Traditional Medicine report, 2005). 
 
1.12.2 Historical importance of natural products as antimalarials.  
The history of the chemotherapy of malaria is deeply linked with the history of herbal 
medicine (Timothy, 2011). Medicinal plants have throughout history played a crucially 
important role in the fight against malaria. From this success based on historical 
natural products being the mainstay of effective antimalarial chemotherapy, there is 
an important need to revert back to investigating new natural products as a main 
source for lead identification for new leads for antimalarial drug discovery. The first 
and most important of them all derives from the bark of a Chinchona plant, more 
commonly known as quinine.  
1.12.3 Discovery of quinine  
 
Quinine was introduced to Europe after a Spanish countess contracted a fever while 
in Peru and was cured by the bark found on the tree giving the new name of countess’s 
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bark. The bark was then taken back to Spain introducing Quinine to Europe in 1638 
(Achan, Talisuna et al., 2011). The bark of the tree was completely dried out and 
ground until a fine powder was achieved, the powder was then added to drinks such 
as wine and taken orally (Achan, Talisuna et al., 2011; Fluckiger & Hanbury, 1874). 
Before being taken back to Europe it was common for Europeans to use European 
and Asiatic plants as fever remedies (Stuart, 2004)   
Quinine was later promoted by Cardinal de Lugo who was the Procurator General of 
the order of the Jesuits. The Jesuits then seized the opportunity and made profit by 
controlling the entire supply of bark into the west thus changing its name to Jesuits 
bark. Due to this in demand supply native trees became threatened and numbers 
started to decline, this the need for cultivation of the came about by Spanish doctor, 
Jose Celestion Bruno Mutis (Stuart, 2004).  
During the 1820s, a couple of well renowned French pharmacists were able to isolate 
an alkaloid from the plant that they named quinine (Stuart 2004). Quinine is a cinchona 
alkaloid belonging to the aryl amino alcohol group of drugs, it is also cladded as a 
basic compound being presented as a salt (Achan, Talisuna et al., 2011). 
Quinine was the most commonly used antimalarial up until the 1920s, after this there 
were just as effective if not more synthetic antimalarials available in the market such 
as chloroquine and amodiaquine (Mojab, 2012), The most important chloroquine 
(Achan, Talisuna et al., 2011). The discovery of quinine led to scientists wanting to 
synthesise the drug to make it more assessable, this resulted in the discovery of 
methylene blue and the dye industry. From this discovery them came the 4- 
aminoquinolines along with amino-alcohols which have been the main malaria 
treatments over the last century (Wells, 2011)  
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1.12.4 Other natural products as antimalarials 
 
There are many naturally derived products that are still in use today as effective 
antimalarials.  One of the most recent pursuits is the development of artemisinin from 
the plant Artemisia annua (see figure below). The plant has played a part in traditional 
Chinese medicine dating back to 168 BCE and was recommended in the 4th century 
as a cure for intermittent fevers (Wright et al., 2010). Artemisinins have had a longer 
correlation to usage and fever in comparison to quinine, however, was discovered as 
an antimalarial in 1971 by the Chinese army. The army screened 2000 plants in hope 
of finding a new antimalarial until they were successful and artemisinin was isolated 
from an extract from the plant. The random screening of 300,000 compounds by 
Walter Reed in 1970 led to the discovery of mefloquine and halofantrine. In the 1940s 




Figure 1.6 Artemisia annua showing the plant artemisinin was discovered from. 
1.12.5 Natural product drug discovery processes for malaria 
The image shown below (Fig 1.7) is a schematic representation of the process of 
natural product drug discovery. A different approach to this method is to select a 
natural product with potential new discovery prospects based upon its ethno-
pharmacological use. This screening method involves both in vitro and in vivo assays 
that are used to screen against the malaria parasite. Following this, the extract is 
purified to isolate the active ingredient with a view to chemical synthesis and scale up. 
Synthesizing natural compounds has enabled researchers to modify the compounds 
resulting in their ability to enhance or suppress certain characteristics such as 
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efficiency and stability within the body. Organic chemists have been inspired by natural 
compounds to create novel drug synthesis (Kohan & Carter, 2005: Ji et al., 2005) 
 
Figure 1.7 Natural product drug discovery process showing the process by which current natural 
drugs may be discovered (Redrawn from Maryam, 2016)  
 
1.12.6 Extraction  
 
The extraction of the natural product is the first step when testing a product for 
antimalarial activity the process involves separating the compound from the raw 
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material. Usually, the product being extracted is carefully pre-washed, dried out and 
then ground. The grinding is an important step when extracting as doing so increases 
the surface area of product that comes into contact with the solvent being used for the 
extraction, thus improving the kinetics of extraction. For the extraction process many 
different solvents can be used depending on the natural product and the specific 
properties they possess. For plants that contain high levels of chlorophyll, hexane can 
be used beforehand to remove the chlorophyll so that the extract can be obtained. 
Hydrophilic compounds require solvents such as methanol, ethanol and ethylacetate 
while compounds that are lipophilic require solvents such as dichloromethane 
(Sasidharan et al., 2010), it is considered crucial that the correct solvent is used in 
order to maximise extraction (Singh, 2008) 
There are several known extraction methods that can be used to obtain the 
compounds from the raw material, some of these methods include sonification and 
heating the raw material under reflux. The method that is widely used however is 
solvent extraction, this was the method used for the extraction process in this study. 
Solvent extraction involves introducing the solvent of choice to the ground surface of 
the raw product to penetrate into the solid matrix, the solutes in the product are then 
dissolved into the solvents used. The solute is then removed from the matrix and the 
solutes are collected (Singh, 2008; Sasidharan et al., 2010). Several factors can 
influence the extraction process some of these include the amount of time the 
compound was exposed to the solvent, the temperature at the time of extraction, the 
ratio of solvent to solid, the particle size of the materials and the properties of the 
solvent used (Singh, 2008). 
When the extraction process is taking place, the finer the particle size, the more 
successful the extraction will be. Extraction is enhanced by the smaller size of the 
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particles due to penetration of the solvents and the diffusion of the solutes becomes 
smoother. However, if the particle size is too fine it will cause later problems upon 
filtration of the solution when drying. When the temperature is increased during 
extraction, it in turn increases solubility and diffusion of the particles. However, if the 
temperature becomes too high, it can cause the solvent to evaporate and compromise 
the quality of the extract. The time the compound is exposed to the solvent it crucial, 
however increasing this time will have no effect on extract once the equilibrium of the 
solute has been obtained within the solution. The amount of raw material exposed to 
the solution will affect the extraction results. More exposer of raw material will produce 
the more extract, too much solvent however till take time to concentrate upon the 
evaporation process (Singh, 2008). 
There are other extraction methods available other than the conventional methods 
mentioned above as these require high solvent quantities and, in some cases, lengthy 
extraction times. There are more green and modern extraction techniques now 
available to combat these problems. These include microwave assisted extraction 
(MAE), pressurized liquid extraction (PLE) and super critical fluid extraction (SFC). All 
three of these new methods have been used to extract compounds from natural 
products successfully, these methods provide a low organic solvent usage with shorter 
extraction times with a higher selectivity (Singh, 2008) 
 
1.12.7 Characterization and identification  
 
There are several ways to identify and characterise specific compounds and a number 
of separation methods are frequently used, thin-layer chromatography (TLC), high 
performance liquid chromatography (HPLC), column chromatography and flash 
chromatography are the main methods used.  TLC works in the same way as many 
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other types of chromatography, having a stationary and mobile phase. The 
compounds that are being separated interact with these two phases. The stationary 
phase in TLC is performed via a plate usually covered in silica gel, a small amount of 
compound is placed upon the gel. The mobile phase involves solvents in which the 
stationary phase would be placed, once placed the compounds would typically travel 
up the gel to later be viewed under a UV light for evaluation. The number of dots found 
upon the gel would represent the amount of compounds within the sample, the 
distance the dots travelled would determine how polar eatch compound was, the 
higher the dot the less polar and this could be a way of determining what compounds 
are present if you have an idea from previous literature on what to expect. TLC is used 
frequently due to the process being inexpensive, simple and rapid (Fair & Kormos, 
2008; Sasidharan et al., 2010). 
HPLC is much more versatile than TLC and is a common practice used within isolating 
natural products and is the most commonly used technique in this field. HPLC contains 
several different types, these include normal and reverse phase chromatography. For 
compounds that possess a higher polarity reverse phase chromatography is usually 
used. HPLC works much like TLC in which it works by using a mobile and stationary 
phase. The process of HPLC starts within the column of the HPLC machine, the 
column in this case represents the stationary phase and again usually consists of 
silica. The column is compact with long carbon chains, the length of the chain 
determines how apolar the column will be. Compounds are placed on the column 
where the mobile phase is started. Water and solvent are passed through the column 
and simultaneously elutes the compound (s). This then separates the compounds 
based on the polar charge where it can then be evaluated to determine the compounds 
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present. HPLC is the most popular method in the fingerprinting of herbal plants, it is 
used to separate the compounds of the natural product (Fair & Kormos, 2008). 
There are techniques for identification that do not require chromatographic techniques. 
The main one being FTIR, but they also include techniques such as immunoassay and 
phytochemical screening assay. Immunoassays work well due to having high 
sensitivity, some techniques in immunoassays are more sensitive than the HPLC 
method as mentioned above. FTIR is a main technique that is used, it is a non-
destructive tool that identifies chemical bonds found within compounds, it works on 
anything that possesses covalent bonds regardless of the sample being organic or 
inorganic.  FTIR typically provides a molecular fingerprint of a compound using the 
compounds unique spectrum. The benefit of using FTIR is that it can be used on whole 
solid material, powders, liquids and even on whole cell analysis. In this study FTIR 
was used on whole sample, this FTIR technique was called Attenuated total reflection 
(ATR). 
ATR spectroscopy, which can also be named as Internal Reflectance Spectroscopy 
(IRS); is mostly used for the study of surface, or the near surface of biological 
materials. It has been used for investigating samples which are too thick for 
transmission measurements or for samples that are opaque (Harrick & Beckmann, 
1974). The spectra obtained from samples which have undergone ATR-FTIR, are 
similar to that of regular transmission spectra, but the ATR samples do not produce 
totally absorbing spectral bands. This is because its effective path-length is controlled 
by properties of the crystal which is used in the apparatus; this reduces the sample 
preparation time. ATR spectra have both reflection and absorption features, meaning 
they cannot always be used in quantitative analysis directly, but can be used to obtain 
information for confirmation of species (Grdadolnik, 2002). 
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ATR functions by measuring what changes are found from vibrations to chemical 
bonds when an internal IR beam is reflected when beamed onto the surface at a 
sample. The IR beam is reflected back into a crystal which has been placed on a 
specific angle, which is shown in the schematic diagram in Figure 1.8. The IR spectra 
is then recorded giving the wavelengths of a sample.  This method is extremely easy 
to use and one of the main advantages of this method is that is not destructive. 
 
 
Figure 1.8 ATF-FTIR showing a redrawn image taken from Thermo fisher. it depicts a schematic 
diagram of ATF-FTIR. It shows the infrared beam passing through the crystal then hitting the detector. 
 
1.12.8 Trametes versicolor  
 
Mushrooms, for many years have been sought after for their many health benefits, 
including, increasing antioxidant activity, enhancing the immune system, managing 
blood sugar levels, improving brain performance and even increasing exercise levels 
(Zhang, Li, Liang & Reddy, 2017). Mushrooms have been found to have antifungal, 
anti-viral and anti-bacterial characteristics, with many commonly used antibiotics 
derived from fungi. Medicinal mushrooms are a plentiful source of immunoceuticals, 
due to the broad immune activity they possess. There are many other natural product 
species that have been known to possess immunologic activity, however some 
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mushroom species and the polysaccharides extracted from them are the most 
thoroughly studied. Certain mushroom species have been studied in both preclinical 
and clinical trials (Standish et al., 2008).  
 There are more than 2000 edible mushroom species described while 270 have shown 
to possess immunotherapeutic properties due to having an effect on hematopoietic 
stem cells, T and natural killer cells (Guggenheim, Wright, & Zwickey, 2014) 
. Of the 270, 50 of these are classified as non-toxic. 6 out of the 50 non-toxic have 
been used in studies on human cancers. One of these mushrooms being Trametes 
versicolor, currently classified as a medicinal mushroom, as a result of passing clinical 
trials (Phase I, II and III) for different specific types of cancer including stomach 
carcinomas in humans. Data indicates that T. versicolor helps patients have disease 
free intervals and improved overall survival rates by boosting the immune system 
(Standish et al., 2008). T. versicolor has become one of the most studied medical 
mushrooms due to its potency (Hobbs, 1995; Stamets, 2000).  
Belonging to the Basidiomycetes class of fungi, Trametes versicolor known more 
commonly as the “turkey tail” is a relatively common species of fungi found worldwide. 
This relatively small polypore fungus is usually found in clusters and has a ring like 
structure with a pale brown/ white underneath (Figure 1.9) (Hobbs, 2004). Like many 
other species it can be spotted virtually anywhere that dead decaying trees, hard wood 
and stumps are left to decompose naturally. Playing a part of a crucial recycler in the 
ecosystem. Like many other natural products, T. versicolor has been used as a 
traditional herbal medicine for many years in Asia, due to its immune system boosting 





Figure 1.9 Trametes versicolor Showing a cluster of Trametes versicolor growing upon decaying 




T. versicolor was discovered to contain two related proteoglycan constituents called 
Krestin (PSK) and polysaccharide peptide (PSP) after a study in Japan showed cancer 
remission after the consumption of T. versicolor (Standish et al,.2008). PSK first got 
approved in Japan in 1977 due to its high molecular weight fractions (Hobbs, 2004). 
Krestin (PSK), was considered safe after a toxicologic assessment found that the 
lethal dose was extremely high. The reports of the toxicity test shown that there were 
no reports of abnormalities in either humans or animals following both chronic and 





Previous studies, have shown PSP, PSK and mycelial extracts as a whole to possess 
a wide spectrum of immunological effects (Standish et al., 2008; Guggenheim, Wright, 
& Zwickey, 2014). Some of these effects are thought to be triggered by having contact 
with immune tissue found within the digestive tract. The cell wall components found 
within T. versicolor such as PSP are hypothesised to have an interaction with the 
Langerhan and dendritic cells within the small intestine. Due to these interactions with 
the digestive tract, many immune cells are subsequently affected. T. versicolor 
extracts, in vitro and in vivo, given orally or as an injection have been known to 
substantially have an impact on the stimulation activity of T cells. They have also been 
found to stimulate bone marrow cells along with natural killer cells and lymphocyte 
killer cells. Along with cells, they have also been shown to increase the level of 
antibodies (Hobbs, 2004)  
Throughout the world, T. versicolor extracts are being used alongside traditional 
cancer-based treatments as an additional treatment. These are taken as prescribed 
medication or as a dietary supplement alongside conventional treatment. For people 
using the extracts as a supplement, they are doing so with the belief it has the ability 
to prevent cancer. It is also believed to prevent viral infection, improve aging and a 
host of problem causing ailments (Stamets, 2012; Kumar & Adki, 2018). When used 
as a cancer-preventive long-term, T. versicolor extracts are thought to have the ability 
to inhibit carcinogenesis via an ability to reduce effects from some known carcinogens 
such as asbestos and tobacco smoke on host cells (Hobbs, 2004). 
When T. versicolor extracts are used alongside chemo and radiation therapy, some 
evidence shows that there is a possibility that it can reduce the risk of secondary 
malignancies that have been induced as a direct result of radiotherapy and 
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chemotherapy. T. versicolor extracts can also protect healthy cells while undergoing 
such treatments (Hobbs, 2004). 
PSP extract from T. versicolor has shown preclinical and in clinical studies to have 
oncologic and immunologic activity for patients who suffer from breast, gastrointestinal 
and lung cancers (Standish et al., 2008).  
Syndromes such as septic shock are a complex syndrome resulting from 
lipopolysaccharide gram-negative bacteria binding to immune cells. Currently, a large 
number of patients are being diagnosed with septic shock daily, because of such large 
numbers new therapeutic possibilities are necessary. Fruiting body extracts from T. 
versicolor have shown to inhibit in vitro binding of lipopolysaccharide. These extracts 
could possess lead structures for further drug development against 
lipopolysaccharide-mediated septic shock (Lindequist, Niedermeyer, & Jȕluch, 2005) 
 
 




1.12.9 Acacia nilotica  
 
Acacia nilotica is considered an important medical plant belonging to the family 
Fabaceae of the genus Accacia (babul) (Rather et al., 2015). It is commonly found 
abundantly scattered across sub-tropical and tropical regions such as Africa, south 
Africa and India. The plant is scented and usually grows between 5 to 20 meters with 
a spherical crown (Ali et al., 2012), branches and stems have a deep dark appearance, 
with a grey/ pink bark. The plant has thick spines for protection and has bright yellow 
flowers when in bloom located at the end of the branches usually between 2 to 3 
centimetres long (Ali et al., 2012). The pods found upon the tree are strongly 
constricted with a hardened exterior, white grey appearance that are hair like and thick 
(Baravker et al., 2008).  
All parts of the tree have been known to have medical benefits in many different 
medical fields. The roots have been used on cancers and tumours, particularly cancers 
of the eye, testicular and ear (Kalaivani & Mathew, 2010). The leaves found upon the 
tree have been used as anti-bacterial, anti-cancer to treat diarrhoea, Alzheimer’s and 
even as dressing for wounds (Kalaivani & Mathew, 2010). The gum on the tree has 
been found to contain anti-asthmatic compounds (Baravker et al., 2008).  The bark of 
the tree is most commonly used as an antibiotic. it has been shown to have 
antimicrobial activity especially on E. coli, S. aureus and Salmonella typhi, curing food 
poisoning in many tropical regions (Banso, 2009). It has also shown signs of being 
anti-fungal. The pods found on A, nillotica have shown to inhibit HIV 1 and also 
Hepatitis C. Extracts of the pod along with crude extract on the root have shown to 
possess high antimalarial activity on P. falciparum. Root extracts have the same effect 
as chloroquine on P. berghei in mice (Jigam, 2010). The pods are also used to treat 
malaria in Nigerian communities (Alli et al., 2016). 
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Phytochemical screening of A. nilotica bark confirmed the presence of glycosides, 
alkaloids, terpenoids and saponins.  Steroids and flavonoids were not found to be 
present in the bark extract, however flavonoids are presentt elsewhere. The bark 
extractions used upon the agar diffusion method has shown antimicrobial activity 
against several different bacterial species, including the main ones as mentioned 
above. Decrease in patients’ blood pressures have been reported after use of a 
methanol extract from the pods. This indicates anti-hypertensive activities that are 
autonomous of muscarinic receptor stimulation (Alli et al., 2016). 
 
 
Extracts obtained from the powder of the bark using different solvents in a study by 
Del (2009), found free-radical scavenging activity via maceration extraction (Alli et al., 
2016). In a similar study by Amos et al (1999) revealed A. nilotica to be a source of 
accessible antioxidants. which can be used as additional supplements in the fight 
against free radical mediated diseases including cancer, inflammation and diabetes.  
It is thought the high scavenging properties could be caused by hydroxyl groups (Alli 




          





1.13 Aims and objectives  
This study aims to investigate the potential prospects of natural products as effective 
antimalarials for future use. Using multidrug resistant Plasmodium falciparum K1, 
Trametes versicolor and Acacia nilotica extracts were investigated to determine the 
level of antimalarial activity. Same extracts were also tested upon HEPG2 and MDBK 
cells to determine the cellular toxicity levels in order to investigate their potential as  




CHAPTER TWO  
 
2.1 Materials and methods  
2.1.1 Collection of samples  
 
The samples of Trametes versicolor were collected from three different woodland 
locations around Manchester. The samples were harvested and left to dry over several 
days.  
2.1.2 Fourier-transform infrared spectroscopy (FTIR) 
 
Once dry the samples were placed in Fourier-transform infrared spectroscopy (FTIR) 
machine to determine that Trametes were of the same species. Tests were performed 
in a Nicolet 5700 FTIR testing machine with a range of 4000 to 800 cm-1, with a 
resolution of 4, a scan rate of 32 and an absorbance mode from which CO2 was 
omitted. Before testing, a blank background was collected as a correction. Files were 
saved as cvs. and spa. The same tests were performed on the extracted product along 
with Acacia nilotica.  
2.1.3 Extraction  
 
The dried samples were blended until only a powder was remaining, the powder was 
then transferred into a container where the stock was built up. The powder was then 
added to 50 ml falcon tubes containing 40 ml ethanol and was left to soak at room 
temperature for 48-hours. The solvent extract was removed using a Pasteur pipette 
and added to falcon tubes and stored in a refrigerator at 4°C until a sufficient amount 
of stock was gathered. The extract was then placed into a 50 ml round bottom flask 
and ethanol removed on a rotary evaporator. The process was repeated until there 
was a sufficient extracted compound for analysis. The flask was then given an ethanol 
wash and the solvent was placed in four Eppendorf tubes with the lids open to enable 
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to ethanol to evaporate leaving behind only the extract. The extract was then stored in 
a refrigerator at 4°C. Methanol and water extractions were previously attempted, 
during method optimisation after process, initial compensations of 0.0204 mg of yield 
showed ethanol to be more effective (Kerry Leigh Dreyer, 2018). 
 
2.1.4 Stock concentration   
 
The extracted materials were dissolved in 1ml DMSO where it was then further diluted 
using complete media. The dilutions used for all experiments were 200, 100, 50, 25 
and 12.5 μg/ml and all concentrations contained <1% DMSO to avoid toxicity to 
Plasmodium falciparum cultures. 
 
2.1.5 In vitro culture of Plasmodium falciparum  
 
All experimental work was carried out at the pathogen laboratory in the University of 
Salford. Experiments were performed under a sterile hood (ESCO class 11 Biological 
safety cabinet) using sterilised techniques and pre-sterilised equipment. All surfaces 
and equipment were sterilized using 70% ethanol. Virkon (Antec international, UK) 
was used for disinfection of waste before autoclave. All protocols by Read and Hyde 
(1993) were followed.   
 
2.1.6 Preparation of complete media 
 
In a 50 ml falcon tube 2.5g of Albumax was added along with 15-20 ml of RPMI 1640 
(containing 25 mM HEPES buffer, sodium bicarbonate, 0.3/ L I-glutamine, 10% human 
serum and 1 ml of washed erythrocytes) and placed upon a vortex until fully dissolved. 
In the falcon tube 2.5 ml of hypoxanthine (1mg/ml), 500 μl of gentamycin (50 mg/ml) 
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and 2.5 ml of glucose (40%). The final mixture was then syringe-filtered into the newly 
opened bottle of RPMI. 10 ml of the complete media were then added to a small culture 
flask and paced into the incubator. 
 
2.1.7 Washing media  
 
A 500 ml bottle of pre-sterilised RPMI 1640 1x (+) L-Glutamine (+) 25mM Hepes 
(Gibco, Life Technologies, UK) without additives was used as washing media 
throughout the study and stored at 2-8oC for up to 2 weeks. 
 
2.1.8 Preparation of human blood culture of Plasmodium falciparum 
Human O+ blood was obtained from the Manchester blood bank. 200 ml of the whole 
blood were transferred into sterile falcon tubes and the remainder into a sterile flask 
and stored in the fridge. The whole blood was centrifuged for 5 minutes at 30,000 – 
31,000 rpm. The supernatant, containing plasma and leukocytes, was removed and 
discarded, leaving behind only the red blood cells (RBCs). RPMI was then added, 
resuspending the RBCs well. The mixture was then centrifuged as mentioned above 
and the process repeated three more times until the RPMI appeared clean. 5-10 ml of 
complete media was then added, resuspended and centrifuged. The final top layer 
was then removed leaving behind RBCs that were at 100% haematocrit. An equal 
amount of complete media was added to give 50% haematocrit. Once washed 0.5 ml 
of the blood was added to the flask containing complete media and mixed well. The 
remaining blood was stored in the fridge at 4 ° for future use.  
 




When predominantly at ring stage with a parasitaemia >10% the culture was selected 
for preservation in liquid nitrogen. The culture was centrifuged at 3,400 rpm for 5 min. 
the supernatant was then removed and the culture brought back to a 50 % haematocrit 
by adding an equal amount of warm complete media. Aliquots of the culture were 
transferred into 2 ml cryotubes and 0.5 ml 20 % dimethyl sulphoxide (sterile filtered 
DMSO, Sigma, UK) in Ringer’s solution (9 g NaCl, 0.42 g KCl and 0.25 g CaCl2/ Litre) 
was added. The cryotubes were then immediately placed into the liquid nitrogen for 
later use.  
 
1.1.10 Revival from liquid nitrogen  
 
The method used to culture the drug resistant K1 strain of P. falciparum was In vitro 
cultivation. The parasites in frozen form are stored in liquid nitrogen. The Cryo vial was 
removed from the liquid nitrogen and placed into an Eppendorf tube. The parasites 
were centrifuged for 90 seconds at 14,000 rpm. The DMSO supernatant was then 
removed and 1 ml of 10% sorbitol was added. The mixture was then resuspended and 
centrifuged for 90 seconds at 14,000 rpm and then supernatant was removed. 1 ml of 
complete media was then added and centrifuged as above, the supernatant removed 
and a final 1 ml of complete media added, mixed well and then placed into the culture 
flask containing the washed blood and RPMI. The flask was then gassed for fifteen 
seconds with a gas mixture of 5% O2, 5% CO2 and 90% N2 and placed into the 
incubator where it was incubated at 37 °C for 48 hours.  
 




To begin a new culture, 10 ml of complete media and 0.5 ml of washed blood was 
added to a 50 ml culture flask and warmed to 37oC prior to the addition of the parasites. 
Approximately 0.5 ml of parasitised blood retrieved from liquid nitrogen was then 
added to the warmed culture media to give a final haematocrit of 5 %. Following 
inoculation, the parasite culture was gassed with a 5 % CO2, 5 % O2 and 90 % N2 gas 
mixture (BOC Limited, UK) and placed in the incubator at 37oC. The culture was left 
for periods of 48 hours in the incubator at 37 °C. To avoid the culture overgrowing 
frequent media changed as fresh non-infected RBCs was needed to maintain a 
healthy culture, along with gas. Generally, the culture was maintained at around one 
– three %.  
 
2.1.12 Synchronisation of Plasmodium falciparum  
 
Sorbitol (5 % w/v) was prepared in distilled water and filtered through a 0.22 µm filter.  
The sorbitol solution was then added directly to pelleted parasite culture (9 ml to 1 ml 
of culture pellet) and incubated for 5 mins at room temperature. Following this, the 
culture was centrifuged at 3,400 rpm for 5 mins and the supernatant was discarded.  
The parasite pellet was then subjected to three washing steps in complete media, 
before re-suspension in complete media at 50% haematocrit. The synchronised 
parasite culture was used to set up a new culture as described previously. 
2.1.13 Slide preparation and estimating parasitaemia  
 
100 μl of the culture were removed from the flask and transferred into Eppendorf tubes. 
The tubes were then centrifuged at 3500 rpm for two - five minutes. The supernatant 
was then removed leaving a small amount of media remaining to mix the pellet. Once 
mixed a small droplet was added to the glass slide and thinly smeared using the end 
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of another slide, leaving behind a clean thin blood smear. The slides were then left to 
air dry in the incubator. Once the slide was completely dry 100% methanol was applied 
to the slide to fix the cells, and once again left to completely dry. The slides were then 
covered in 10% Giemsa stain and left for twenty minutes. The Giemsa stain was then 
washed off where the slide was then left to dry for a final time.  
The parasites were examined using the immersion oil lens at 100x magnification. The 
parasites were then observed to check the life stage and level of parasitaemia. The 
total number of infected RBC was divided by the total number of RBC then X100. This 
was repeated three times in three different fields and an average was taken to 
determine the final percentage of parasitaemia. Upon this the formula C1 V1 = C2 V2 
was used to obtain the desired level of parasitaemia for an experiment or cultivation.  
 
1.2.14 Plate assay for Plasmodium falciparum  
 
The parasites were first washed to remove any dead or fragmented parasites to avoid 
inaccurate results. The parasitaemia then diluted to 1% using freshy washed blood 
and complete media. The haematocrit was maintained at 2.5%. The experiment was 
set up on a black bottom 96 well plate. Firstly, 100 μl of the drug dilutions 200, 100, 
50, 25 and 12.5 μg/ml of each compound was added in triplicates on the plate. 100 μl 
of the blood, parasite and media were then added to each well. A positive control was 
used containing 100 μl of media and 100 μl of the parasitized blood along with a 
negative control containing blood and media. The outer well on the plate was filled 
with 200 μl PBS to avoid the plate drying out. The plates were then placed into 
chambers, along with a small cap of distilled water, where there were gassed for three 
minutes with the 5% O2, 5% CO2 and 90% N2 gas mixture and incubated for either 72 




2.1.15 SYBR Green Microtiter plate assay  
 
The SYBR Green solution was prepared by adding 3.3 μl of SYBR Green into 10 ml 
of PBS. After the incubation period 140 μl of the media was removed from each of the 
wells and 140 μl of the SYBR Green solution was added. The plate was then left in a 
dark room for 40 minutes while the SYBR green stained the parasites. The plate was 
then taken to the microplate fluorescence reader with the measure parameters set to 
gain 70 and set to read plate.  
 
2.2 MTT HEPG2/ MDBK 
2.2.1 Media preparation  
 
From a fresh bottle of RPMI containing L- glutamine, 60 ml of the RPMI was removed 
as set aside. To the bottle of RPMI 50 ml of fetal bovine serum, 5 ml of penicillin at 1% 
and 5 ml of L- glutamine were added to make the complete media. 
2.2.2 Culturing of cells  
 
First the flask was placed under the microscope to determine the level of cells in the 
flask. The media was then removed and the flask was washed with 1x PBS, the flask 
was washed three times. Once washed, 3-5 ml of trypsin was added and the flask was 
incubated at 37°C for three minutes. After incubation the flask was gently tapped and 
place under the microscope to ensure the cells were fully detached from the flask. 8 
ml of media were then added to the flask and the entire contents transferred into a 
falcon tube. The falcon tube was then centrifuged for five minutes at 1500 rpm. The 
supernatant was then removed. In a fresh flask 14 ml of media and 1 ml of culture 




2.2.3 MTT Plate assay  
 
The cells were diluted accordingly in 96 well plates to give 4 x 103 cells (100μl) per 
well. On a 96 well clear flat bottom plate 100 μl of the culture were added to each well, 
with 200 μl of media placed on the outer wells to avoid the inner well drying out. The 
plates were then left in the incubator for 24 hours. The next day the compound dilutions 
were added 200, 100, 50, 25, 12.5 and 6.25 μg/ml. The plates were then incubated for 
five days.  
Once the plates were ready to read 50 μl of MTT solution was added to each well and 
the plates were incubated in a dark environment for a further three hours. After the 
three hours all the media plus MTT solution was removed from each well. In each of 
the wells 150 μl DMSO was added and the plate was immediately placed into the plate 
reader  
 
2.3 Data analysis  
 
Microsoft Excel was used to transfer the data from the plate readers and calculate 
parasite growth and inhibition. Graph Pad was another programme used to generate 
the graphs and acquire the IC50 values from each of the experiments. The tables were 







3.1 Results  
3.1.1 Extract of Trametes versicolor. 
 
Briefly two methods were attempted: ethanol and methanol extraction. The methanol 
extraction failed to yield adequate extracts and further experiments were confined the 
ethanol extracts for Trametes. 
Initial ethanol extraction methods reliant on maceration of the samples in ethanol and 
ethanol evaporation overnight resulted in poor yield (Fig. 3.1). Subsequently, solvent 
from the macerated ethanol suspension was removed by rotary evaporation which 
yielded better powder extracts of 0.0204 mg (Fig. 3.2 & 3.3). The methanol and ethanol 
extracts of Acacia nilotica produced good yields of 0.0394 mg.  
 
Figure 3.1 Ground and whole Trametes versicolor showing the Trametes versicolor once 




Figure 3.2 Auto evaporation of Trametes versicolor showing the ethanol extract after auto-
evaporation. 
Figure 3.3 Final ethanol extract after having a wash with DMSO and and left to dry. This was the 
extract used in this study. 
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3.2 Fourier-transform infrared spectrometry (FTIR) 
3.2.1 FTIR of Trametes versicolor  
 
The samples of Trametes versicolor were collected from three different locations in 
the North West of England (Delamere forest, Worsley woods and Ellesmere park 
Eccles). In order to confirm they were of the same species, each sample was 
characterised by Fourier-Transform infrared spectrometry (FTIR) before extraction to 
avoid mixing different species. It was observed that all the stretching modes were 
similar amongst all the samples. FTIR fingerprint was also performed on the ground 





















ATR-FTIR Delamere Forest Trmetes versicolor 







Figure 3.4. FTIR analysis of Trametes versicolor found in Delamere forest, Worsley forest and 




















ATR-FTIR Worsley Trametes versicolor





















ATR- FITR Ellesmere park Eccles Trametes versicolor




Figure 3.5 FTIR ground Trametes versicolor showing wavenumber alongside absorbance of the 
FTIR fingerprint on the sample once ground into a powder. 
 
 
Figure 3.6 FTIR of the Ethanol Trametes versicolor showing wavenumber alongside absorbance of 
the FTIR fingerprint of the final extract. 






FTIR fingerprint spectra analyses were also carried out for A. nilotica. The first FTIR 
fingerprint performed was on the whole pod (Fig. 3.7) and after grinding (Fig 3.8). FTIR 
fingerprints were then produced for the ethanol and methanol extractions (Fig 3.9 & 
3.10).  All figures show four series per graph.  
 
Figure 3.7 FTIR of Acacia nilotica whole showing the wavenumber alongside absorbance of the FTIR 




Figure 3.8 FTIR of Acacia nilotica ground showing wavenumber alongside absorbance of A. nilotica 




Figure 3.9 FTIR analysis of Ethanol Acacia nilotica showing wavenumber alongside absorbance of 
the ethanol extraction of A. nilotica.  
 
Figure 3.10 FTIR analysis of methanol Acacia nilotica showing wavenumber alongside absorbance 
of the methanol extraction. 
Similarity of the FTIR spectrum for the different collections was used to confirm 












3.3 Drug efficacy  
Experiments to test the efficacy of the Trametes versicolor were performed as 
described in the methodology section in Chapter 2. Briefly, 2-fold serial dilutions of the 
Trametes ranging from 200, 100, 50, 25 and 12.5 μg/ml were tested against P. 
falciparum K1 strain with synchronised cultures initiated at trophozoite or ring stages 
for 48- or 72-hour incubations respectively.  All experiments were carried out in 
duplicated and the averaged IC50 values for each were calculated. 
For the Trametes ethanolic extract, the 48-hour value was IC50 45.5 ± 1.12 μg/ml (Fig. 
3.11) and the 72-hour producing an average IC50 of 27.47 ± 1.09 μg/ml (Fig. 3.12). 
For Acacia extractions the 48-hour IC50 value ethanol extract of A. nilotica was 49.38 
± 1.06 μg/ml (Fig. 3.13) and the 72-hour reached achieved 50 % growth inhibition at 
37.3 ± 1.07 μg/ml (Fig 3.14). For A. nilotica methanolic extract, the final IC50 of the 48-
hour averaged at 20.2 ± 1.11 μg/ml (Fig 3.15), the 72-hour gave an IC50 of 44.3 ± 1.06 
μg/ml (Fig 3.16). 
 
 
3.3.1 48-hour Trametes versicolor  
 
The T. versicolor ethanol extraction incubated for 48-hours produced an average IC50 
of 45.54 ± 1.12 μg/ml. Despite the increase in IC50 values, the compound still shows 
potency prospects. The first IC50 value giving 58.71 ± 1.04 μg/ml and the second 32.37 




Figure 3.11 48-hour Trametes versicolor showing parasitaemia against drug concentrations. Each 
line represents thee triplicate experements. 
3.3.2 72-hour Ethanol Trametes versicolor  
 
The two sets of data shown below produce an average IC50 of 27.47 ± 1.09 μg/ml.  
Both sets indicate the compounds are active with antimalarial properties. The first IC50 
value giving 27.50 ± 1.15 μg/ml and the second 27.45 ± 1.10 μg/ml (Fig 3.12). 
 
 
3.3.3 48-hour Ethanol Acacia nilotica  
 
The average IC50 produced from the ethanolic extract of A. nilotica after 48-hour 
incubation is 49.38 ± 1.06 μg/ml, giving a higher IC50 than that of the 72-hour. Similar 
Figure 3.12 72-hour Trametes versicolor showing parasitaemia against drug concentrations. Each 
line represents three triplicate experiments. 
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to that of T. versicolor, there was an increase in IC50, however antimalarial properties 
were still present (Fig 3.13).  
 
Figure 3.13 48-hour Ethanol Acacia nilotica showing parasitaemia against `drug concentrations. 
Each line represents three triplicate experiments. 




The two graphs below produce an average IC50 of 37.3 ± 1.07 μg/ml. The average 
value shows antimalarial activity, however slightly lower than that of Trametes. The 
first IC50 value giving 43.33 ± 1.13 μg/ml and the second 31.44 ± 1.01 μg/ml (Fig 3.14). 
 
Figure 3.14 72-hour Ethanol Acacia nilotica showing parasitaemia against drug concentration. Each 




3.3.5 48-hour Methanol Acacia nilotica  
 
The results obtained from the 48-hour incubated methanol extract of A. nilotica 
produced the most promising results found in this study. The average IC50 obtained 
was 20.2 ± 1.11 μg/ml, which is significantly lower than the 72-hour incubation. Both 
data sets produced almost identical results with the first IC50 value being 20.25 ± 1.07 
μg/ml and the second 20.24 ± 1.15 μg/ml (Fig 3.15).  
 
Figure 3.15 48-hour Methanol Acacia nilotica showing parasitaemia against drug concentrations. 
Each line represents a triplicate experiment. 
3.3.6 72-hour Methanol Acacia nilotica  
 
 
The average IC50 results were 44.3 ± 1.06 μg/ml. Although the highest average IC50 
value of the 72-hour the results still show to possess antimalarial activity. The first IC50 




Figure 3.16 72-hour Methanol Acacia nilotica. showing parasitaemia against drug concentrations. 
Each line represents three triplicate experiments. 
 
3.4 MTT assay  
The standard MTT (3-(4. 5-dimethyltrazol-2-yl)-2,5-diphenyl terrazolium bromide 
assay was performed to investigate the toxicity of the compounds. The HepG2 cells 
were incubated with dose range (200, 100, 50, 25 and 12.5 μg/ml) of the different 
extracts. Cisplatin was used as a control alongside the compounds to validate the MTT 
assay (Fig. 19). Due to better yield and more promising results the ethanol extracts 
were carried forward as the methanol extract for A. nilotica was not reached. The 
following results were obtained after a five-day incubation period upon exposure to the 
compounds.  
The ethanol extraction of T. versicolor produced the highest IC50 value for the HEPG2 
cell line providing a value of 51.6 ± 1.2 μg/ml (Fig. 3.17). While the ethanol extract of 
A. nilotica was found to be more toxic with an IC50 of 29.1 ± 1.07 μg/ml Fig. 3.18).  
 




The average IC50 obtained from the ethanol extraction of T. versicolor on the HEPG2 
cell line was 51.6 ± 1.2 μg/ml. The first IC50 value giving 50.11 ± 1.15 μg/ml and the 
second 58.18 ± 1.34 μg/ml (Fig 3.17). 
 
Figure 3.17 HEPG2 Trametes versicolor showing cell viability against T. versicolor drug 
concentration. Each line represents a triplicate experiment.  
3.4.2 HEPG2 Acacia nilotica   
 
From the two data sets of the ethanol extrication of A. nilotica on the HEPG2 cell line, 
an average IC50 of 29.1 ± 1.07 μg/ml was obtained. The first IC50 value giving 34.54 ± 
1.28 μg/ml and the second 23.85 ± 1.25 μg/ml (Fig 3.18). 
 
Figure 3.18 HEPG2 Acacia nilotica showing cell viability against A. nilotica drug concentration. Each 
line representing a triplicate experiment. 
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3.4.3 HEPG2 Cisplatin  
 
Cisplatin was used alongside T. versicolor and A. nilotica as a control, the average 
IC50 obtained for the HEPG2 cell line was 40.29 ± 1.07 μM/ml. The first round gave an 
IC50 of 44.13 ± 1.4 μM/ml. The second round have a final IC50 of 36.46 ± 1.10 μM/ml 
(Fig 3.19).  
 
Figure 3.19 HEPG2 Cisplatin showing cell viability against cisplatin drug concentration. Each line 














3.5 Therapeutic index.  
The therapeutic index is used to determine the compounds toxicity, this determines 
whether or not the compound is going to be passed to the next stage of testing.   
For the 72-hour set of experiments alongside HEPG2 T. versicolor produced a 
therapeutic index of 1.87 while A. nilotica gave 0.7. The 48-hour produced similar 
results with T. versicolor giving 1.13 and A. nilotica 0.58.  
  
 72-hour  48-hour  
Trametes versicolor  1.87  1.13  
Acacia nilotica  0.7  0.58  
Table 1. Therapeutic index showing the final therapeutic indexes of the compounds tested alongside 












Chapter 4  
Discussion  
 
Fortuitously discovered natural product leads have been the mainstay of antimalarial 
chemotherapy for centuries. Much of these discoveries were informed through the 
keen observations of traditional ethnopharmacological practices. The structural 
diversities and complexities of natural product-derived scaffolds together with their 
innate affinity for biological receptors offer an advantage, yielding the most effective 
antimalarials known to date. Unfortunately, reliance on newly-evolved high-throughput 
screening and discovery platforms has led to decreased focus on natural product 
leads, resulting in a significant decrease of such leads in the past 3 decades. 
This study, focusing on A. nilotica and T. versicolor has confirmed the exciting potential 
of natural product extracts to contain novel antimalarial leads for future drug design.  
The study focused on exposing the extracts to multidrug resistant P. falciparum K1 
strains. The studies were carried out in the pathogen lab at the University of Salford, 
using in vitro study alongside non-parasitized human blood as a control. The results 
of the whole extract in vitro evaluation offer promising potential for natural product lead 
discovery and further optimisation through active compound analysis. The high IC50 
values obtained in this study could be down to several factors, a main one being that 
whole extract were used which could show varied results dependant on the nature of 
the natural product and appropriate solvent used. The solvents used in this study were 
ethanol and methanol, as previous studies had shown water extractions to be of little 
effect. From literature and previous studies, IC50 values that have been obtained to be 
over 100 µg/ml are classed as ineffective as an anti-plasmodial drug. 50-100 µg/ml is 
deemed to be of low activity and 10-50 is considered to be of moderate activity. An 
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IC50 value ≤ 10 µg/ml is classed as highly active again Plasmodium and would be 
considered for future research and development (Clarkson et al., 2004). 
The 72-hour ethanol extract of T. versicolor produced the lowest IC50, with an average 
IC50 of 27.47 ± 1.09 μg/ml, and the 48-hour incubation had an average IC50 value of 
45.5 ± 1.12 μg/ml. While both incubation times produced IC50 values of moderate 
Plasmodium activity, this natural product could be taken further for investigation. The 
results were corroborated in a study at Salford University by Kerry Leigh Dreyer 
(2018), showing the ethanol extraction T. versicolor IC50 value to be 46 μg/ml (personal 
communication, unpublished data).  
The T. versicolor component used in this study was the whole extract of the fruiting 
bodies. A recent study by Benson et al., (2019), found there was a highly distinguished 
immune activating effect in the mycelium of T. versicolor when compared to its fruiting 
body. Furthermore, the mycelium and fruiting body have distinctly different biological 
and immune modulating effects on the body. Mycelium helped in triggering the 
immune cell activation whereas the fruiting body increased cytokine induction. 
Investigating the mycelium effects on the P. falciparum as oppose to the fruiting body 
could possibly give improved IC50 values and would be a recommended course for 
analysis in future experiments (Benson et al., 2019). 
Fungi along with plants and bacteria are known to produce secondary metabolites. 
These metabolites provide a crucial source of effective pharmaceutical products. 
Secondary metabolites found within fungal endophytes have been described as 
pharmaceutically useful crops. Bioactive metabolites within fungi possess a wide 
range of biological activities including antibiotic, antitumor and anti-inflammatory. 
Public interest in secondary metabolites is growing resulting in drug discovery 
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research including bio-chemical and molecular techniques from higher medicinal fungi 
(Devi et al., 2020; (Kivrak, & Karababa, 2020). 
For further development of pharmacologically interesting mushrooms and mushroom 
compounds, cultivation is a crucial step to ensure demand is met sustainably and in a 
standardised manner. Whole fruiting bodies, extracts derived from mycelium and 
fruiting bodies along with isolated compounds are all suitable for cultivation. Foraging 
in the wild, mushroom farming, harvest and cultivation of mycelium are all ways of 
gathering adequate supplies. Extraction methods can be performed with dry or fresh 
as long as suitable solvents are used. There is a possibility that pure compounds can 
be gathered from the natural product, cultivated and later by chemical induced or 
altered synthesis. It is often known for a natural compound to serve as a lead 
compound, with the prospect of a high variety of derivatives. As most mushroom 
species are easily and economically cultivated already, the need for mushroom 
compounds to be genetically modified is not needed at this time. One of the most used 
polysaccharides from mushrooms, which have been developed for therapeutic agents, 
have been derived from Trametes versicolor which has been used in this study. 
Intracellular protein polysaccharides (IPS) which are isolated from Trametes versicolor 
has high efficiency as an immunomodulator and anti-tumour agent (Cui et al., 2007; 
Wang et al., 2017). Polysaccharide peptide and polysaccharide keratin from T. 
versicolor are examples of mushrooms being collected from the wild/farmed and 
chemically synthesized. After production of such extracts, simple capsules, tablets, 
shots and teas can be commercialised for human use (Lindequist, Niedermeyer, & 
Jȕluch, 2005; (Pinheiro, Michelin, Vici, de Almeida, & de Moraes, 2020). 
The best anti-plasmodial activity from the experiments was seen with ethanol 
extracted Acacia nilotica, yeilding average IC50 values of 37.3 ± 1.07 μg/ml at 72-hour 
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incubations, and methanol extracted A. nilotica, yielding average IC50 values of 20.2 ± 
1.11 μg/ml at 48-hour incubations. This produced the lowest IC50 out of all experiments 
regardless of incubation time, indicating peak antimalarial activity. This value indicates 
a successful level of anti-plasmodial activity and would need further studies using 
fractionation techniques to identify active compound and further reduction in IC50 
value.  
The current experiments were conducted with whole extracts of seed pods. Published 
literature on the medicinal value of A. nilotica, suggests differential medicinal potential 
in the different parts of the tree (e.g. bark, leaves, roots) and there is a great need and 
demand for isolation and identification of new compounds from each part of the tree. 
Henc, expansion of the current experiments to investigate the whole extract from the 
other parts of the tree are likely to yield more avenues for investigation. In further 
studies on A. nilotica, it was seen to have possible interactions between serotonin 
receptors that are linked with hypertension (Gilani et al., 1999; Alli et al., 2016; Omara, 
2020. This could indicate a potential mode of action for this natural product lead in 
malaria. Drug repositioning studies (Matthews et al., 2013) have reported antimalarial 
activity in patent expired drug library screens on serotonin inhibitors, among other 
classes of drugs. This does provide a further line of investigation for the next phase of 
optimisation 
 As A. nilotica displays high radical scavenging properties, indicating there is high 
activity due to the occurrences of phenolic compounds. These individual compounds 
still require further research for identification. Until then, their introduction into the 
pharmaceutical industry is not possible (Kalaivani & Mathew, 2010). Some 
antioxidants that have been isolated from A. nilotica such as Umbelliferone, have been 
used in assisting the prevention of cancer and ageing. This antioxidant eliminates 
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oxidative species responsible for carcinogenesis via DNA alteration. (Singh et al., 
2009).  
There have been previous studies on A. nilotica, using aqueous extractions of the root. 
These extractions were eluted and its antimalarial properties were tested on mice that 
had been infected with P. berghei. The extractions produced positive results showing 
the reduction of parasite prevalence in relation to dose response. The mice treated 
with the extracted root compound shown a significant increase in overall survival to 
that compared with the control subjects (Alli et al., 2016). In a relatively recent study, 
the leaves found upon the Acacia tree once extracted using an ethanol solvent, were 
found to have an average IC50 value of 1.29 μg/ml after a 48-hour incubation period. 
Significantly lower than the IC50 obtained in this study, however this study focused on 
the pods, which averaged at 37.3 ± 1.07 μg/ml. The results obtained from the 48-hour 
incubated methanol extract of A. nilotica produced the most promising results found in 
this study. The average IC50 obtained was 20.2 ± 1.11 μg/ml.   
Cultivation of A. nilotica plants in a sustainable way would be needed to achieve drug 
development on a pharmaceutical level. Further in-depth research is still needed to 
reveal the full potential this medical plant has to offer to mankind (Alli et al., 2016)  
The T. versicolor and A. nilotica extracts were further tested on HEPG2 cell lines to 
test compound toxicity. Cisplatin was used as a control alongside the compounds 
ensuring the experiment worked accordingly.  
The therapeutic index is used to determine the compounds toxicity, to determine 
whether or not the compound is going to be passed to the next stage of testing. The 
therapeutic index is worked out by dividing the IC50 of the MTT assay by the 
Plasmodium IC50.  
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For the 72-hour set of experiments alongside HEPG2 T. versicolor produced a 
therapeutic index of 1.87 while A. nilotica gave 0.7. The 48-hour produced similar 
results with T. versicolor giving 1.13 μg/ml and A. nilotica 0.58. All compounds in this 
study would be deemed too toxic for human consumption when used in the whole 
extract form. A non-cancerous cell line and repeated experimental would be needed 
to obtain a more reliable therapeutic index outcome.   
T. versicolor extracts are being used alongside traditional cancer-based treatments as 
an additional treatment. PSP extract from T. versicolor have shown preclinical and in 
clinical studies to have oncologic and immunologic activity for patients who suffer from 
breast, gastrointestinal and lung cancers.  When T. versicolor extracts are used 
alongside chemo and radiation therapy, some evidence shows that there is a 
possibility that it can reduce the risk of secondary malignancies that have been 
induced as a direct result of radiotherapy and chemotherapy (Habtemariam, 2020). 
Similarly, the roots of A. nilotica have been used on cancers and tumours, particularly 
cancers of the eye, testicular and ear (Kalaivani & Mathew, 2010). A. nilotica is an 
easily accessible source of antioxidants, which can be used as additional supplements 
in the fight against free mediated diseases including cancer.  
Β-glucans and their protein derivatives, mainly protein-polysaccharides, attract the 
most attention due to their potential biological functions and non-toxic characteristics. 
They have been found to have vital roles in anti-tumour, anti-oxidant, anti-viral and 
immunomodulating activities (Gan, Lie Li 2015; Wang et al., 2017). 
Interestingly, HepG2 cell lines have been used as the gold standard to decipher 
antimalarial in vitro for most published work. HepG2 cell lines themselves are derived 
from hepatic carcinoma. Given that both T. versicolor and A. nilotica possess anti-
cancer properties as stated above, the increased IC50 values from this study may be 
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a result of the confounding effect the antcancer properties of thisextract may have on 
the HepG2 cell line. Hence the low selectivity index should be further investigated 
using a non-cancerous human cell line. 
Therefore, exposing both T. versicolor and A. nilotica extracts to cancer cell lines such 
as HEPG2 to determine toxicity has proven ineffective in obtaining a reliable 
therapeutic index. Non-cancerous human cell lines would be needed for further study 
in order to obtain a toxicity level required for next stage testing in a development for a 
novel drug. Toxicity could also be a direct factor of the DMSO used within this study, 
while extractions were taking place. Both T. versicolor and A. nilotica are natural 
products used on a daily basis across the world for many different reasons. Therefore, 
a toxic result should not have been the outcome of this study.  
It is vital that selected natural products have a therapeutic index that is favourable. 
The parasite must be completely eliminated or inhibited from the body while having 
minimal toxicity to the host. Such discoveries have proven difficult in the past. Multiple 
natural products have displayed the ability to inhibit protozoal growth, with only a small 
number having selective toxicity to the parasite only. Drugs that act upon the 
biochemical target unique to the Plasmodium parasite are needed as these have little 
to no effect on the host, therefor being deemed safe for consumption (Singh, Krishna 
& Kumar 2020).  
To conclude, further studies on both T. versicolor and A. nilotica is required given their 
potent antimalarial activity. The isolation of the active compounds within the natural 
products could be an exciting new research idea for the future. Using HPLC analysis 
would be a useful technique in determine the compounds present that have these 
antimalarial properties. As this in vitro study focused on multidrug resistant K1 stain of 
P. falciparum, there is a potential to test the same compounds upon different strains 
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in the future to determine its effectiveness. The same principle could also be applied 
to different species of Plasmodium. A study on all five Plasmodium’s currently known 
to affect humans would be of interest to compare the effectiveness of the natural 
products on the different species. Finally, given that many antimalarials also possess 
anti-cancer activity in vitro, the use of the gold standard HepG2 cell lines to test cellular 
toxicity and derive selectivity indices may result in important leads being discarded 
due to erroneous inferences resulting from an inappropriate testing platform. A safe 
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